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ABSTRACT 
Type 1 diabetes (T1D) is a chronic disease that affects 1.25 million people in the 
United States.  There is no known cure and patients must self-manage the disease to 
avoid complications resulting from blood glucose (BG) excursions.  Patients are more 
likely to adhere to treatments when they incorporate lifestyle preferences.  Current 
technologies that assist patients fail to consider two factors that are known to affect BG: 
exercise and alcohol.  The hypothesis is postprandial blood glucose levels of adult 
patients with T1D can be improved by providing insulin bolus or carbohydrate 
recommendations that account for meal and alcohol carbohydrates, glycemic excursion, 
and planned exercise.  I propose an evidence-based decision support tool, iDECIDE, to 
make recommendations to improve glucose control by taking into account meal and 
alcohol carbohydrates, glycemic excursion and planned exercise. iDECIDE is deployed 
as a low-cost and easy to disseminate smartphone application.   
A literature review was conducted on T1D and the state-of-the-art in diabetes 
technology.  To better understand self-management behaviors and guide the development 
of iDECIDE, several data sources were collected and analyzed: surveys, insulin pump 
paired with glucose monitoring, and self-tracking of exercise and alcohol.  The analysis 
showed variability in compensation techniques for exercise and alcohol and that patients 
made unaided decisions, suggesting a need for better decision support. 
The iDECIDE algorithm can make insulin and carbohydrate recommendations.  
Since there were no existing in-silico methods for assessing bolus calculators, like 
iDECIDE, I proposed a novel methodology to retrospectively compare insulin pump 
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bolus calculators.  Application of the methodology shows that iDECIDE outperformed 
the Medtronic insulin pump bolus calculator and could have improved glucose control. 
This work makes contributions to diabetes technology researchers, clinicians and 
patients.  The iDECIDE app provides patients easy access to a decision support tool that 
can improve glucose control. The study of behaviors from diabetes technology and self-
report patient data can inform clinicians and the design of future technologies and 
bedside tools that integrate patient’s behaviors and perceptions.  The comparison 
methodology provides a means for clinical informatics researchers to identify and 
retrospectively test promising insulin blousing algorithms using real-life data. 
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1 INTRODUCTION 
1.1 Lack of Diabetes Management Technologies that Account for Lifestyle Preferences  
Diabetes is a complex disease that affects 29.1 million US citizens and type 1 
diabetes (T1D) is a subtype that affects 1.25 million people in the US [1]. T1D is a 
chronic condition with no known cure in which a person’s pancreas does not produce 
insulin, a hormone required to regulate carbohydrate and fat metabolism in the body.  The 
lack of insulin causes hyperglycemia, also referred to as high blood glucose.  The state of 
hyperglycemia leads to long term complications, such as damage to kidneys, eyes, heart 
and nervous system, as well as increased mortality rates from heart disease [2,3].   
T1D requires that individuals self-manage blood glucose and administer insulin 
therapy to compensate for the lack of insulin produced by the pancreas.  Insulin pump 
therapy mimics a normal functioning pancreas by delivering preprandial (i.e. before 
mealtime) bolus insulin and continuous basal insulin to compensate for carbohydrate 
loads and out of target blood glucose levels.  Bolus insulin doses are calculated based on: 
carbohydrate load, insulin to carbohydrate ratio, the actual blood glucose level, the target 
blood glucose level, insulin sensitivity factor, and the insulin on board [4,5].  While self-
management of blood glucose can be empowering, the amount of data that must be 
tracked can be overwhelming [6].  Because the calculation to determine an insulin bolus 
is complex and error prone, insulin pumps and blood glucose meters often have 
embedded bolus calculators which use proprietary algorithms to lessen the cognitive 
burden on patients by automating the computation of bolus insulin doses.  Even with 
assistance from consumer health informatics applications, such as clinical decision 
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support systems, patients still fail to meet glycemic goals [7].  In addition to delivering 
insulin at mealtimes, patients on intensive insulin therapy are recommended to consume 3 
meals a day and to check blood glucose 4-10 times a day, which includes checking before 
every meal and before bedtime.  At least 150 minutes of moderate exercise spread over 
several days a week is also recommended for all types of diabetes, particularly with T2D 
in order to manage obesity [8].  Those with type 2 diabetes may have different 
pharmacologic approaches to maintain glycemic control, such as daily oral medications.  
Barriers to initiating insulin therapy in both T1D and T2D have been identified, such as 
fear of hypoglycemia and reluctance to accommodate the timing of insulin doses [9]. 
While bolus calculators have been shown to lead to better glucose control [10], 
they have limited capabilities as they currently only account for out-of-target blood 
glucose levels and planned carbohydrate loads.  Although there are many variables that 
can influence glucose levels, e.g. stress, illness, medications, etc., in this work we will 
focus on two lifestyle preferences that are known to affect blood glucose: alcohol and 
exercise [11–17].  While the immediate effects of the carbohydrates in some types of 
alcoholic beverages may increase blood glucose, the alcohol itself may cause delayed 
hypoglycemia.  Exercise generally results in lowering blood glucose levels during the 
activity and may cause delayed hypoglycemia as well.   Allowing for flexibility is 
important, as it is known that regimented, invariant self-management care is not effective 
in diabetes care [18–20], and can lead to therapeutic non-adherence in the absence of 
accounting for individual lifestyle preferences. 
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Closed-loop devices (a.k.a. artificial pancreas) are based on complex 
mathematical models that aim to improve glycemic control by automating insulin 
delivery and other hormones related to controlling blood glucose.  These closed-loop 
devices are not ready for commercial use and there are few studies that have reported 
specifics on how the proposed algorithms perform when compensating for exercise or 
alcohol.  Similarly, existing mobile applications (apps) are sub-optimal for meeting 
evidence-based guidelines for glucose control as they do not account for exercise or 
alcohol consumption.  In the US, there are few FDA-regulated mobile apps that provide 
bolus calculators. Of the apps that do provide such calculators, they do not account for 
exercise and alcohol [21].  
Clearly, better tools are needed to assist type 1 diabetes patients with insulin 
dosing, particularly when trying to account for multiple factors simultaneously that may 
impact glucose control.  The hypothesis is postprandial blood glucose levels of adult 
patients with T1D can be improved by providing insulin bolus or carbohydrate 
recommendations that account for meal and alcohol carbohydrates, glycemic excursion, 
and planned exercise. 
1.2 Research Aims 
Aim 1: Review state of the art on relevant clinical evidence and technology 
Conduct a literature review to understand how exercise and alcohol affect blood 
glucose absorption in adult T1D patients.   Review current technologies available to self-
manage glucose control, with particular emphasis on those that support patients as they 
decide how much insulin to take when consuming meals and/or alcohol and exercising.   
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Aim 2: Investigate self-management behaviors of adults on insulin pump therapy 
Describe real-life self-management behaviors in T1D adults on insulin pump 
therapy. Contrast self-reported, self-management diabetes behaviors from patients versus 
behaviors recorded by diabetes technology (insulin pumps and glucose sensors) using a 
combination of qualitative and quantitative methods. Confirm the need for decisional 
support tools to help patients incorporate personal lifestyle choices, such as planned 
exercise and alcohol consumption, into diabetes self-management. 
Aim 3: Propose iDECIDE, a novel evidence-based bolus insulin dosing decision aid that 
accounts for glycemic excursions, carbohydrates, planned exercise and alcohol 
Refine the algorithms currently used by patients to compute preprandial insulin 
boluses to develop iDECIDE, an evidence-based bolus insulin decision aid that accounts 
for glycemic excursions, meal’s carbohydrates, planned exercise and alcohol 
consumption. 
Aim 4: Propose and apply novel methods for retrospectively evaluating the accuracy of 
the proposed iDECIDE insulin bolus algorithm 
There is a lack of methods that use real-life data for evaluating the performance of 
insulin dosing algorithms.  Current methods use data from controlled clinical 
environments (e.g. clinical trials) or simulators to evaluate the performance of insulin 
dosing algorithms.  Retrospective, low-risk methods that use real life data could provide 
valuable preliminary results to inform future clinical trials. We propose a systematic 
approach to analyze the effectiveness of glycemic control interventions using real life 
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data and demonstrate the method by evaluating the performance of the iDECIDE decision 
aid. 
Aim 5: Design and deploy the smartphone app iDECIDE 
Design and deploy the proposed insulin bolus decision aid as an iOS smartphone 
application. Improve the application through usability testing. 
1.3 Outline of Dissertation 
This chapter provided a brief introduction to T1D and stated the lack of evidence-
based decision support tools that account for personal lifestyle preferences such as 
exercise and alcohol, which are known to affect blood glucose levels. Chapter 2 delves 
deeper into the motivation of this work by reviewing in more detail the state of the art of 
current evidence on how carbohydrates, insulin, alcohol and exercise affect blood 
glucose.  We also identify the current decision support systems available to help patients 
achieve better glycemic control. Chapter 3 focuses on understanding the challenges faced 
by those on insulin pump therapy and their self-management behaviors.  Chapter 4 
specifically targets self-management behaviors of patients on insulin pump therapy when 
compensating for exercise and alcohol.  Chapter 5 describes the evidence-based decision 
aid, iDECIDE, and how it compensates for carbohydrates, blood glucose, alcohol and 
exercise.  Chapter 6 introduces the novel methods that we propose for retrospectively 
comparing the efficacy of insulin bolus recommendations using real-life data.  The results 
from retrospectively comparing iDECIDE against a conventional decision comprise 
Chapter 7.  Chapter 8 addresses the steps required to design and deploy iDECIDE as an 
iOS smartphone app.  A conclusion is provided in Chapter 9.  
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2 STATE OF THE ART ON CLINICAL EVIDENCE AND DECISION SUPPORT 
SYSTEMS FOR DIABETES MANAGEMENT 
2.1 Introduction 
This chapter summarizes the results of the completed literature review on: 1) 
relevant clinical evidence related to patient’s daily lifestyle choices, including 
carbohydrates, alcohol consumption and exercise, as well as the effects of insulin on 
blood glucose, and 2) the state of the art on available technologies (decision support 
systems) to help diabetes patients compensate for everyday life preferences.  The 
outcomes of this chapter correspond to Aim 1. Preliminary results of the completed 
literature review were presented as a poster at the American Medical Informatics 
Association Annual Symposium 2014 (APPENDIX A.1) and as a conference paper at 
MEDINFO 2015 [22,23] (APPENDIX B.1). 
2.2 Background 
Type 1 diabetes (T1D) is a chronic disease in which a person’s immune system is 
involved in the destruction of insulin-producing β-cells (beta cells) in the pancreas [24].  
T1D can be diagnosed at any age, but the disease is most likely to be diagnosed during 
childhood.  There is no cure for T1D and what causes the disease is not well understood 
and there is no way to prevent the disease, but it is likely that both genetics and 
environment play a role [24].  Individuals with diabetes must engage in self-management 
to maintain glycemic control by regularly checking blood glucose levels with a meter or 
monitoring with a continuous blood glucose sensor. Patients must also deliver insulin 
with syringes, insulin pens or insulin pumps.   
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Providers are motivated to prescribe the best treatments to their patients in order 
to achieve better outcomes, but self-management behaviors have been found to have a 
greater impact on blood glucose levels than the decisions made by physicians [18].  
Failing to provide patient-centered care, i.e. care that respects the wants, needs and 
preferences of the patient, places patients in a position where they must adapt to pre-
existing treatment protocols and guidelines [25].  Patients with chronic diseases, like 
diabetes, are better motivated to make and sustain behavior changes if they receive 
patient-centered care [26].  Allowing for flexibility is important as regimented, invariant 
self-care routines are not effective and can lead to non-adherence [18–20].  One such 
self-care behavior that can empower patients with diabetes is self-monitoring of blood 
glucose.  Self-tracking blood glucose data can be overwhelming for patients, as even 
those who are knowledgeable can fail to meet glycemic goals [27].  Many decision aids 
and technologies have been developed to enable patients to better integrate blood glucose 
data into the decisions they make as they engage in self-care.  For example, Bluetooth 
technology supports data exchange between blood glucose meters and continuous glucose 
monitors with insulin pumps and smartphone apps, while patient portals allow patients to 
upload their data and grant access to their providers. 
The objective of Aim 1 is to two-fold: 1) understand the current technologies 
available that provide decisional support to patients with diabetes as they self-manage the 
disease, and 2) understand two lifestyle preferences that have an impact on glucose 
levels: exercise and alcohol.     
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2.3 Methods and Materials 
A literature search was conducted to understand the pathophysiology of diabetes 
and the effects of alcohol and exercise on postprandial blood glucose.  The literature 
review described here applies to sections 2.4.1 – 2.4.4 and 2.4.6.  PubMed, Google 
Scholar and insulin pump manufacturer manuals were used to identify articles and 
resources for inclusion.  The Medtronic MiniMed, Inc. insulin pump user manual was 
identified and included in the literature review [28]. This insulin pump manufacturer was 
identified by the Mayo Clinic endocrinology clinicians as a widely-used device amongst 
their patient population.  Google Scholar was used to identify guidelines and/or white 
papers on type 1 diabetes.  The search criteria for guidelines was “‘guideline’ OR 
‘standard of care’ AND ‘diabetes’” and the search criteria for white papers was “type 1 
diabetes pathogenesis.”  For each search criteria, the dates of inclusion were limited from 
2012 to 2016.  The top 20 results for each search strategy were included in the search for 
a total of 40 results from Google Scholar.  Two search strategies were used with PubMed 
to identify articles for the acute effects of exercise and alcohol.  For exercise articles, the 
search included articles with exercise in the title and diabetes and glucose in the title or 
abstract.  Articles were excluded if they included type 2 diabetes, risk, mortality or 
coronary in the title or abstract; the root words neuro and recommend were also excluded 
from the title or abstract.  For alcohol, the articles were included if they had alcohol and 
diabetes in the title and excluded if the title or abstract contained type 2 diabetes, 
prevalence, mortality or smoking.  Both exercise and alcohol searches were limited from 
2010 to 2016 and restricted to human only studies.   
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In addition to the literature review, we met with an endocrinologist and diabetes 
care team to further understand diabetes and to discuss current clinical challenges that 
patients with diabetes encounter.  We participated in a guided training session with a 
diabetes nurse educator at the Mayo Clinic Arizona Simulation Center that included 
hands-on experience with insulin pumps, meters and continuous glucose monitors.  We 
also reviewed existing insulin pump technologies commercially available in the United 
States (US) that are approved by regulatory entities such as the Federal Food and Drug 
Administration (FDA).   
2.4 Results 
There were 229 identified articles from the search strategies of which all of the 
titles and abstracts were screened.  Articles that described the short-term glycemic impact 
of alcohol and/or exercise were included in the review as well as guidelines and/or white 
papers about type 1 diabetes.  There were 216 articles that were excluded, see Figure 2.1: 
Flow diagram of article and resource selection for literature review. for reasons for 
exclusion.  During the full text review of the remaining 13 articles an additional 12 
articles were identified from author citations that were not found in the literature searches 
and were included in the final review for a total of 25 resources. 
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Figure 2.1: Flow diagram of article and resource selection for literature review. 
 
2.5 Discussion 
2.5.1 Effects of carbohydrates on blood glucose 
Glucose is a simple sugar that is released into the bloodstream as a result of the 
digestion of food containing carbohydrates.  When blood glucose levels are high, 
properly functioning β-cells in the pancreas secrete insulin into the bloodstream [24].  
The secretion of insulin, along with other metabolic processes within the body, maintain 
tight glycemic control in healthy individuals.  When the pancreas does not secrete insulin 
in response to increasing levels of glucose in the blood, as in the case of damaged β-cells 
in individuals with T1D, hyperglycemia, or high blood sugar, ensues.  Chronic 
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hyperglycemia can lead to organ damage and other complications [2].  The goal of 
insulin therapy for individuals with T1D is to dose insulin in such a way that it mimics as 
closely as possible the secretion of insulin from healthy β-cells in the pancreas into the 
blood stream. 
2.5.2 Effects of insulin on blood glucose 
Insulin is a hormone that regulates the metabolism of carbohydrates, proteins and 
fats and is responsible for delivering glucose found in the bloodstream into cells, 
particularly adipose, liver and muscle cells [24].  Every individual reacts differently to 
carbohydrates and insulin, and as such, the amount of insulin required to offset the 
glycemic-load from food containing carbohydrates is different for each individual and its 
value is referred to as an insulin to carbohydrate ratio (ICR) [29].  The ICR indicates how 
many carbohydrates one unit of insulin will cover, i.e. the amount of glucose that insulin 
will move from the bloodstream into cells.  This ratio can be coupled with carbohydrate 
counting, a method for estimating the carbohydrate content of foods, in order to adjust the 
amount of insulin for injection. Another important ratio to consider is the insulin 
sensitivity factor (ISF), which is also referred to as the correction factor (CF), which also 
is adjusted for each individual [29].  CF is described as how much 1 unit of fast-acting 
insulin will lower blood glucose levels over the course of 2-4 hours during a fasting or 
pre-meal state.  Patients with T1D can use the following equation from Colin, et.al. 
(Equation 2.1) [29], to compute the amount of insulin needed to adjust for a carbohydrate 
load and/or an out of range blood glucose reading. 
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Equation 2.1: Standard Insulin Dosing Equation 
 
𝑈 =
𝑐𝑎𝑟𝑏𝑠
𝐼𝐶𝑅
+
𝑐𝐵𝐺 − 𝑡𝐵𝐺
𝐶𝐹
− 𝐼𝑂𝐵 
 
In Equation 2.1, the variable U represents the units of insulin to deliver.  The first 
fraction of the equation, “carbs/ICR”, calculates the relationship between the grams of 
carbohydrates (carbs) intended to be consumed covered by insulin, or the ICR.  ICR is 
calculated as 450/TDD, where the total daily dose of insulin (TDD) = body weight (lbs.) 
x 0.23.  The second fraction in the equation calculates the difference between the actual, 
or current blood glucose (cBG) level and the target blood glucose level (tBG) and divides 
the difference by the CF.  CF is calculated as 1700 mg/dL divided by TDD.  The final 
segment of the equation subtracts the insulin on board (IOB), i.e. the theoretical amount 
of insulin remaining in the body from previous insulin boluses.  Adjusting for previous 
boluses avoids insulin stacking, or dosing more insulin than is needed, which can lead to 
hypoglycemia, or low blood sugar levels.  Hypoglycemia is an acute situation that if left 
untreated can result in neurologic damage and even death.  Hypoglycemia can be averted 
by reducing the bolus insulin, increasing food intake, or a combination of both [30].  
While hypoglycemia poses immediate danger, hyperglycemia, has delayed effects that 
can lead to cardiovascular disease and organ damage.  Hyperglycemia can be managed by 
dosing insulin [31]. 
2.5.3 Effects of exercise on blood glucose 
The American Diabetes Association (ADA) Standards of Care guidelines from 
2016 state that regular physical activity is important for maintaining health and fitness for 
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those diagnosed with diabetes [8].  The guidelines suggest that people with diabetes 
should participate in 150 minutes of moderate intensity (50% to 70% of maximum heart 
rate) physical activity per week.  The guidelines caution that taking insulin and engaging 
in moderate exercise may cause hypoglycemia, but in the case of intense exercise blood 
glucose levels may rise [8].   
García-García, et.al. conducted a systematic review and meta-analysis in 2015 on 
ten studies to find the rate of change of glucose during exercise [32].  The meta-analysis 
showed that continuous exercise at moderate intensities resulted in a rapid decrease in 
glucose.  Fewer studies were available for the analysis of intermittent high intensity (IHI) 
exercise and the results were conflicting showing either a rapid decrease in glucose or a 
slight increase in glucose.  Guelfi, et.al. conducted an observational study with 7 
participants with type 1 diabetes on the difference in blood glucose response between 
moderate exercise and IHI exercise [33].  Each participant was monitored at rest and 
during 30 minutes of moderate exercise and IHI exercise.  Moderate exercise decreased 
glucose levels an average of 80 mg/dL while IHI exercise decreased glucose levels 52 
mg/dL when compared to resting.  Another review was done in 2015 by Bally, et. al. 
found corollary results that high intensity exercise may lead to hyperglycemia and that 
incorporating an IHI exercise routine may produce more predictable declines in blood 
glucose [34]. 
The most common study design amongst the literature on exercise was a 
randomized crossover design with 7 to 12 participants that was often preceded by 
obtaining a baseline measurement for reference, such as rest, peak heart rate or VO2max 
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(peak oxygen uptake, an indicator or cardiorespiratory endurance) with 2 of the 6 studies 
being a specific subtype where the timing of meals and/or insulin were controlled as well 
[35–38] and [39,40].  
In a recent study in 2015, Tonoli, et. al. used an exhaustion test to obtain VO2max 
on 7 participants and a baseline of blood glucose at rest [35].  Each participant then 
exercised twice for 22 minutes, with the order of the type of exercise randomized 
between continuous moderate exercise at 70% VO2max or IHI with 1 minute of intense 
intervals at 90% VO2max.  This study found that there was a significant drop in blood 
glucose between rest and exercise, and although the moderate exercise reduced blood 
glucose an average of 50 mg/dL and IHI exercise an average of 35 mg/dL, the differences 
between the types of exercise were not found to be statistically significant.  A 
randomized crossover study by Shetty, et.al. in 2015 identified an inverse u-shape 
between exercise intensity and glucose requirements [36].  A euglycemic clamp was used 
as 9 participants engaged in exercise on four occasions randomized at various levels of 
VO2max (35, 50, 65 and 80% VO2max) and glucose requirements were recorded during the 
exercise.  Glucose infusion rates increased for exercises with intensities up to 65% of 
VO2max with statistical significance up to 50% VO2max.  This study found that glucose was 
not required at when participants engaged in exercise at 80% VO2max. 
In 2007 Guelfi, el. al. conducted a similar study in which they determined VO2max 
for 9 participants and then randomized the order of 45 minutes of rest, IHI exercise and 
moderate exercise at 40% VO2max [37].  During each type of activity blood glucose levels 
were maintained with glucose infusion delivered intravenously.  Although exercise did 
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require significant amounts of glucose infusion to maintain blood glucose, the differences 
in the amount of infused glucose were not significantly different between the two types of 
exercise.   In 2013, Yardley, et.al failed to establish a difference in the reduction of blood 
glucose between 45 minutes of continuous exercise at 60% VO2max and resistance 
training in their study that included 8 participants [38].  In their study, aerobic exercise 
reduced blood glucose by 60 mg/dL while resistance training had a reduction of 28 
mg/dL, but the differences were not significant. 
Campbell, et.al. conducted a study in 2014 where 8 participants engaged in 45 
minutes of exercise at 70% VO2max with the order of the insulin delivery 1 hour before 
exercise randomized between no change in the regular bolus to a 75% reduction in the 
regular insulin bolus accompanied with a meal [39].  This study identified a 120 mg/dL 
drop in glucose for both arms of the study, with the insulin reduction arm having a lower 
risk for hypoglycemic events.  Mauvais-Jarvis, et.al. used a relatively large cohort with 
12 participants and determined the VO2max [40].  Then 60 minutes of exercise at 70% 
VO2max was held constant while the amount of insulin delivered before mid-morning 
exercise was randomized between a regular bolus or a 90% reduction of the regular 
insulin bolus.  Sucrose was provided partway through the exercise event for 8 of the 
participants during the regular insulin bolus arm of the study while the bolus reduction 
arm did not experience any hypoglycemic events.  This study found that blood glucose 
levels fell an average of 90 mg/dL during both arms of the study. 
Although the study conducted by Mallad, et.al. focused on the use of glucose 
tracers, they recorded the glucose levels of 75 minutes of moderated exercise (estimated 
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50% VO2max) for 16 participants and found that the average drop in glucose was 120 
mg/dL [41]. 
In a review of the current literature on exercise and type 1 diabetes, Kourtoglou 
synthesizes the findings from various studies to describe the biological mechanisms at 
play that effect glucose levels during exercise [11].  Kourtoglou explains that insulin 
sensitivity increases during physical activity while glucose production from the glucagon 
stores in the liver increases as well.  While this response generally leads to hypoglycemia, 
it can produce hyperglycemia in certain types of intense exercise.  Most types of exercise, 
including light, moderate, and some types of vigorous exercise will cause blood glucose 
levels to drop, which may cause hypoglycemia during or after completion of the physical 
activity.  Exercise-induced hypoglycemia can be mitigated by consuming carbohydrates 
when engaging in exercise. 
2.5.4 Effects of alcoholic beverages on blood glucose 
The ADA guidelines suggest that for patients who drink alcohol they should do so 
in moderation, that is 2 or fewer drinks per day for men and 1 or fewer drinks per day for 
women [8].  The difficulty with alcohol and diabetes is the risk of hypoglycemia, which 
has been documented to contribute up to 6% of hypoglycemic admissions in the 
emergency department amongst patients treated with insulin [42].  Depending on the 
specific content of the drink, alcoholic beverages can be a source of carbohydrates and/or 
can cause hypoglycemia due to the metabolic effects of alcohol.  Evidence on alcohol and 
type 1 diabetes is sparse, difficult to compare due to differences in study design and 
beverage types used, and results are often contradictory.  Although most studies show 
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that consuming alcohol with a meal increases the risk of hypoglycemia the next day 
[17,43–45], the results at 2-3 hours following the ingestion of alcohol vary.  Studies by 
Koivisto et.al. and Gin et.al. show that there is no postprandial difference when 
consuming alcoholic beverages with an appreciable carbohydrate content (e.g. red wine) 
in conjunction with a meal [43,45].  Both studies had a small number of participants 
(n=10, n=5, respectively) when participants were given identical meals on two different 
occasions with one served with alcohol.  Two other studies by Turner, et. al. and 
Richardson, et.al. show that postprandial levels after consuming alcohol with little to no 
carbohydrate content (e.g. spirits) with a meal were 45-55 mg/dL lower when compared 
to an equal volume of water served as a control in combination with an identical meal 
[17,44].  Again, both studies had a small number of participants, 6 and 16, respectively.  
In addition to drinking in moderation, the ADA suggests that alcohol is consumed with a 
meal in order to lessen the potential for acute and delayed hypoglycemia [8]. 
2.5.5 Other factors that influence blood glucose 
There are various factors that can affect blood glucose levels that include food, 
medication, activity, and biology that can be found in the literature and in patient forums.  
As discussed in section 2.5.1 and 2.5.4, carbohydrates and alcoholic beverages have an 
effect on glucose levels, but to a varying degree, so does the fat and protein content of 
foods and caffeine levels of beverages.  There are various medications that can cause 
blood glucose to increase or decrease, with steroids being an example of a medication 
that can cause glucose levels to spike.  Stress, illness, hormones, lack of sleep and scar 
tissue can also cause glucose levels to rise.  The scope of this work is to focus on patient 
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preferences, and most of the factors listed here are items that patients may have very little 
control over and are difficult to measure or quantify and therefore were not chosen to be 
included in the development of the iDECIDE decision aid at this time. 
2.5.6 Decision support systems for maintaining glycemic control 
Sophisticated decision support tools that are under development are referred to as 
the artificial pancreas, or closed-loop systems.  These systems attempt to almost 
completely remove the burden of monitoring glucose and delivering insulin by 
incorporating sensor-augmented insulin pumps with predictive insulin delivery 
algorithms that account for carbohydrates and learn from historical patient dose-response 
data [46].  These systems have consistently shown increased percentage of time in target 
glucose ranges while also averting hypoglycemic events [47–50].  Currently these 
devices are not ready for commercial use, though there are ongoing initiatives between 
academia and industry that may aim to bring the technology to the marked in the coming 
years [48].  While the results from several studies demonstrate that closed-loop devices 
have the potential to improve glucose control [51–54], few studies have reported 
specifics on how the proposed algorithms performed when compensating for exercise and 
alcohol [55–58]. 
Similarly, existing mobile applications (apps) are sub-optimal for meeting glucose 
targets.  There has been a proliferation of smartphone apps for diabetes care.  In 2009 
advice from 137 mobile diabetes applications for diabetes were compared against 
evidence-based guidelines.  It was found that there were obvious gaps between the 
evidence-based recommendations and the functionality of the apps [59].  Another review 
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found that the majority of the apps available for diabetes offered only one or two 
functionalities that support self-management, such as documentation, data sharing, 
analysis, visualization, education, reminders, and therapeutic recommendations [60].  
While reviewers found that improved usability scores correlated with that apps that 
supported fewer functions, patients may result to using multiple apps to gain access to 
needed functions, thus complicating self-management even further.   
GlucoseBuddy, an app that was developed by SkyHealth LLC and released in 
2008, had over 100,000 downloads in 2013.  GlucoseBuddy allows users to log glucose 
levels, insulin doses, nutrition, and exercise.  Researchers conducted a randomized 
controlled trial with GlucoseBuddy by recruiting 72 participants with T1D over the 
course of 6 months.  For this study, data was shared with diabetes educators who 
reviewed the data and sent personalized text messages to participants in the intervention 
group on a weekly basis.  Results showed a significant improvement in glycemic control 
for participants in the intervention arm of the study [61]. 
Behavior change is an important part of diabetes self-management, and 
unfortunately there are few apps that include behavior change techniques, and those that 
do are not based on validated behavioral theories.  Even fewer apps that have been 
reviewed provide tailored support using data collected from the user to improve 
adherence to self-management [62].  Additionally, the FDA has determined that it will 
only regulate apps that qualify as medical devices, leaving patients with little more than 
app ratings to guide them as they select apps to assist with diabetes self-management.  
Further complicating the diabetes app market is that there appears to be several insulin 
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dosing calculators available as apps, a criteria that qualifies them as a medical device, 
which are not FDA approved [63].   
In 2015, 46 insulin dosing calculators were identified that perform simple 
mathematical calculations using carbohydrate intake and blood glucose [64].  From those, 
30% did not document the formulas used, and 67% carried a risk of inappropriate output 
dose recommendations that violated basic clinical assumptions.  In the US there are few 
FDA-regulated mobile apps that provide bolus calculators, and none of them take into 
account exercise and alcohol [21] 
In order to lessen the burden of manually calculating insulin boluses, bolus 
calculators have been developed and disseminated to patients.  Bolus calculators have 
been deployed as simple stand-alone sliding scales, but at present bolus calculators are 
primarily integrated into electronic medical devices [65].  For example, glucose meters 
and insulin pumps have embedded bolus calculators.  It is estimated that one million 
people use insulin pumps worldwide with Medtronic MiniMed, Inc. reporting 70% of the 
market share and approximately 400,000 pumps in use in the USA [66,67].  At the outset 
of this study many of the patients at the Arizona Mayo Clinic used Medtronic insulin 
pumps, which influenced our choice to focus on Medtronic pumps for the remainder of 
this study.  
2.5.7 Medtronic’s decision aid for calculating pre-meal insulin boluses 
Current bolus calculators embedded into insulin pumps do not account for 
exercise or alcohol.  They implement variations of Equation 2.1 when computing bolus 
insulin.  Here we describe the algorithm used by the insulin pump manufacturer, 
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Medtronic, which uses Equation 2.1 as the base equation.  In order to determine IOB, the 
insulin pump requires that a parameter called the active insulin time be set by the user or 
care provider.  The active insulin time is used to back calculate how much insulin may 
still be left in the patient’s bloodstream from previous boluses in order to prevent insulin 
stacking which can lead to hypoglycemia.  Additionally, ICR, CF and low and high target 
glucose parameters are programmed into the insulin pump bolus calculator, which values 
are generally determined by the provider. 
The Medtronic Bolus Wizard which is embedded into insulin pumps uses 4 
variations of Equation 2.1 which are based on current blood glucose levels and how they 
compare to individualized target blood glucose ranges for the patient [28]. 
1. If cBG is greater than tBG, IOB is included in the calculation as well as the 
blood glucose and food correction portions of the equation.  If the blood 
glucose correction minus IOB is a negative number, then only the food 
correction portion of Equation 2.1 is used in the calculation. 
2. If cBG is less than tBG, IOB is not included in the calculation.  The blood 
glucose correction is then added to the food correction. 
3. If cBG is at tBG, then only the food correction portion of the equation is used. 
4. If no cBG is provided, then only the food correction portion of the equation is 
used. 
These data required for calculating bolus insulin, along with data acquired via 
glucose meters or continuous glucose monitor systems, changes to pump settings, patient-
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reported carbohydrate intake, and other information generated by the insulin pump are 
recorded in tabular format as depicted in Figure 2.2. 
 
Figure 2.2: Screenshot of condensed raw insulin pump data which includes: 
timestamp, blood glucose reading received from a connected meter (BG), type of 
bolus delivered (Type), the bolus amount selected by the patient (Select) and 
actually delivered (Deliver) by the pump, the bolus suggestion (Est), insulin pump 
settings (High, Low, ICR, ISF), user-reported carbohydrates (Carbs, BG reading 
used for calculation (BG), the insulin on board (IOB), readings from a continuous 
glucose meter (not shown), changes made to insulin pump settings (not shown), and 
other information generated internally by the insulin pump (not shown).  In the 
example above, the bolus calculator made two insulin recommendations, 0 units at 
8/9/2016 18:54 and 0.9 units at 8/11/2016 23:23, both of which the user overrode and 
selected 0.1 units to be delivered.  Six additional insulin boluses were delivered by 
the participant without accessing the insulin pump bolus calculator.  Also, the 
patient checked blood glucose 6 times over the course of three days. 
 
Calculating bolus insulin using Equation 2.1 is a difficult mental task for most 
people to perform.  Bolus calculators have been incorporated into glucose meters and 
insulin pumps to lessen the cognitive burden of calculating bolus insulin.  The use of 
bolus calculators has been shown to greatly improve patient’s accuracy when calculating 
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an appropriate insulin bolus.  Despite the advantages provided by bolus calculators 
embedded in insulin pumps, these decisional aids do not account for exercise and alcohol, 
two of many variables (e.g. stress, medications, etc.)  that are known to affect glucose 
levels.  During most types of light to moderate exercise blood glucose levels will 
decrease, while sustained vigorous exercise may actually increase glucose.  The acute and 
delayed effects of alcohol conflict from one study to another.  It may be the case that 
postprandial hypoglycemia may be averted by consuming an alcoholic beverage that 
contains a high carbohydrate to alcohol ratio (e.g. beer, drinks mixed with regular soda) 
in conjunction with a meal. 
While the artificial pancreas may eventually provide a closed-loop system, this 
technology has not yet completely addressed the effects of exercise and alcohol and is 
still not ready for patient use.  Smartphone apps that support self-management of diabetes 
and provide insulin bolus calculations also fail to account for exercise and alcohol and 
very few have been approved for use by the FDA.   
The current state of decisional aids for patients with diabetes leads us to believe 
that our aim to develop a decision support system deployed as a smartphone app, 
iDECIDE, that accounts not only for meals and glycemic excursions, but also for exercise 
and alcohol would be beneficial to improve glucose control. 
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3 SELF-MANAGEMENT BEHAVIORS IN ADULTS ON INSULIN PUMP 
THERAPY: WHAT ARE PATIENTS REALLY DOING? 
3.1 Introduction 
Successful diabetes management requires behavioral changes to improve 
glycemic control and achieve better health outcomes.  While there have been many 
studies that focus on children, adolescents and emerging adults, little is known about the 
self-management behaviors of adults on insulin pump therapy.  One study that included 
all ages found that less than one third of the participants had achieved recommended 
glycemic control (HbA1c < 6.5%) and that those with excellent control were more likely 
to exercise regularly, self-monitor blood glucose more frequently and have fewer 
instances of missing an insulin dose [68].  Most studies on adherence have relied upon 
indirect methods of measurement which introduce error and bias, such as patient self-
report via interviews and surveys [69].  Some of the limitations that arise from self-report 
methodologies can be overcome by using direct methods to assess adherence by using 
objectively gathered data from diabetes technology [70].  This chapter identifies and 
quantifies self-management behaviors in adults with type 1 diabetes who employ insulin 
pump therapy (Aim 2) by using direct and indirect methods and correlates the behaviors 
with glycemic outcomes based on participant’s individual glucose targets.   
One month of raw insulin pump data in tabular format was downloaded from 19 
participants.  For each participant, there were approximately 10,000 rows of data and 30 
columns documenting user entry of carbohydrates, function overrides (e.g. adjust basal 
rates), blood glucose meter readings, continuous glucose monitoring output, calculations 
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for determining insulin bolus recommendations, and other internal pump messages and 
functions.  Computer programs were written to automatically analyze each row of data in 
order to quantify the observed frequency of expected behaviors such as insulin bolusing, 
checking blood glucose and recording carbohydrate intakes, as well as other interaction 
observed with the insulin pump based on the data collected and stored by the insulin 
pump.  The following behaviors were automatically extracted with computer programs 
based on a sample of insulin pump data in Figure 2.2: 1) the participant accessed the 
bolus calculator on two occasions, 2) the participant selected a different amount of insulin 
bolus to deliver on both occasions, 3) six additional insulin boluses were delivered by the 
participant without accessing the insulin pump bolus calculator, and 4) the patient 
checked blood glucose 6 times over the course of three days.  
Over 4,000 insulin pump interactions were analyzed from the 19 participants to 
ascertain behaviors.  There was inter-subject variability in adherence to most of the 
minimally expected behaviors for self-management and a high frequency of behaviors 
not recommended for self-care.  Additionally, there there was little use of advanced 
insulin pump features despite the participants having an average of 11 years of insulin 
pump therapy.   Adherence to delivering insulin boluses was high and consistent with 
96.8% (5.7) daily adherence.  Daily documentation of carbohydrates and blood glucose 
checks had lower rates of adherence and high variability, 76.6% (31.7) and 60.0% (32.5), 
respectively.  Bolusing without accessing the insulin pump bolus calculator, which is in 
general a not recommended behavior, occurred in 13.0% (16.9) of the delivered boluses 
while selecting a square waveform, an advanced pump feature, was used in 6.4% (10.8) 
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of delivered boluses.  Higher frequency of adherence to daily behaviors correlated with a 
higher number of glucose readings at target.  We also found that 87% of boluses 
delivered by patients resulted from accessing the insulin pump bolus calculator which 
indicates that patients generally use the bolus calculator to deliver insulin boluses.  This 
finding suggests that in many instances patients may benefit from an insulin dosing 
algorithm that accounts for additional lifestyle preferences, such as exercise and alcohol.   
Preliminary results of this work were presented as posters  at the 2015 Diabetes 
Technology Conference and at the American Diabetes Association (ADA) 76th Scientific 
Session [71,72] (APPENDIX A.2 and A.3).  The ADA poster was also selected to be part 
of a moderated poster discussion on “Insulin-related Issues and Other Topics in Diabetes 
Care.”  Chapter sections 3.2 through 3.5 represent the extended version of those posters 
which has been published in the Journal of Diabetes Science and Technology [73] 
(Appendix C.1). 
3.2 Background 
Optimizing glucose control in patients with type 1 diabetes mellitus (T1D) is 
known to reduce microvascular and macrovascular complications [2]. The intensive 
insulin therapy needed to accomplish glycemic goals can be delivered either via multiple 
daily injections or continuous subcutaneous insulin infusion devices, also referred to as 
insulin pump (IP) therapy.  However, intensive insulin therapy alone is not sufficient to 
achieve desired glycemic goals. Successful diabetes self-management requires behavioral 
changes in order to achieve glucose targets.  The 2016 ADA Standards of Care 
Guidelines outline the behaviors required for daily self-management, including 
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recommendations to monitor blood glucose (BG) 6-10 times per day, and dose prandial 
insulin 3-4 times per day as it relates to carbohydrate intake [8].  Adherence to 
recommended behaviors is difficult to achieve and maintain for a variety of reasons, with 
many barriers, such as social, contextual, psychological, educational and economic [74].  
Diabetes technology (e.g. insulin pumps and glucose meters) and other consumer health 
information technologies (e.g. telemedicine and smartphone apps) have been found to to 
improve diabetes self-management adherence and improve glycemic control [75]. 
As technology for diabetes has advanced, so have the informatics capabilities of 
IPs and BG monitors.  Devices store objectively measured data that can be downloaded 
and used to quantify behaviors and outcomes.  IPs store data such as the bolus amount 
suggested by the insulin pump bolus calculator (IPBC), the bolus amount selected by the 
patient, carbohydrates entered into the IP by the patient, and BG levels from a connected 
BG monitor and/or a continuous glucose monitoring system (CGMS). 
Adherence to self-management behaviors (SMB) such as carbohydrate intake, 
administering insulin boluses to cover meals, and monitoring of BG have been studied in 
children, youth and emerging adults (18-26 years old) with various criteria, methods and 
sources of data, including IPs [76–80].  Although IP therapy has been found to improve 
glycemic control, suboptimal adherence can result in poor glycemic control  [77,81]. 
There is a lack of studies that describe SMB in adults with T1D. The objective of this 
study was to use IP data to analyze and characterize common behaviors related to insulin 
bolus dosing, BG monitoring and carbohydrate intake observed in adults with T1D, and 
to correlate those behaviors with glycemic outcomes. 
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3.3 Methods and Materials 
3.3.1 Study recruitment 
After Institutional Review Board approval, we recruited adults with T1D from an 
outpatient academic endocrinology practice.  We identified potential participants at 
routine quarterly visits and they were contacted to set up a recruiting appointment.  After 
participant consent we remotely gathered data after 30 days of participation.  Therefore, 
data was collected after the appointment with the provider and well before the next 
quarterly appointment.  
3.3.2 Participant selection 
We adopted the following inclusion criteria: patients who had been under the care 
of the endocrinology team for at least one year, 18-70 years of age, non-pregnant, English 
speaking, and using the same IP, Medtronic MiniMed, Inc [28].  The exclusion criteria 
included: fragile health, limited life expectancy, records of mental health problems, 
advanced vascular disease or micro-vascular complications, known history of severe 
hypoglycemia or advanced atherosclerosis.  Participants were part of a larger study that 
collected additional data to compare insulin bolus algorithms [82,83]. 
3.3.3 Data collection and cleaning 
Participants’ IP data was downloaded in its source format (i.e. spreadsheet).  IP 
data included carbohydrates recorded by the participant, BG levels from CGMS or 
capillary BG monitor or both, amount of insulin suggested and delivered by the pump, 
and personalized pump settings and BG targets which may have varied over the course of 
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a 24-hour period. Computer programs were written to automate the process of 
quantifying the IP behaviors and glycemic outcomes.  
We identified over 4,000 interactions with the IP in this study. Using code, we 
removed duplicate BG readings that occurred in within 4 minutes of each other since 
CGMS sent readings every 5 minutes.  We included in the analysis values that were 
entered manually, recorded from IP connected BG meters and CGMS.  We did not 
identify any means to identify BG readings that resulted from user-error, and as such, no 
BG values recorded with the IP were excluded after the data cleaning process.   
3.3.4 Minimally expected self-management behaviors 
Following O’Connell, et.al. and Driscoll, et. al. the minimally expected daily 
SMB for glycemic control were defined as: 1) counting carbohydrates 3 or more times 
per day (assuming at least 3 meals per day), 2) delivering an insulin bolus 3 or more 
times per day to correspond to those meals, and 3) checking BG 4 or more times per day 
(once for each meal and before bedtime) [77,78].  These behaviors were quantified on a 
daily basis for each participant and two-sided, unequal t-tests were used between those 
using capillary glucose monitoring and CGMS. Fisher’s exact test was used to compare 
adherent days to non-adherent days when considering BG readings that were within 
target.  These parameters were assessed because they could be directly derived from 
IP/CGMS data. 
The correlation of the above three diabetes SMB was analyzed with BG 
outcomes.  Glycemic control was addressed on a daily basis by categorizing BG as low, 
at target or high based on each participant’s personalized BG targets. The number of BG 
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readings within the target range for the participant over the course of a 24-hour day were 
compared to the total number of BG readings.  BG readings were obtained from manual 
entry, synchronized glucose meter or CGMS. 
3.3.5 Insulin bolusing behaviors 
How often participants selected the same, smaller or larger insulin bolus that was 
suggested by IPBC was evaluated. Additionally, the number of times the IPBC was 
accessed was and this value was used to calculate the percentage of IPBC overrides. 
Finally, participants may have opted to deliver insulin boluses without consulting 
the IPBC. They may have changed the waveform (e.g. normal to square), which is 
considered an advanced IP feature. The delivered boluses for each participant were 
counted and used to calculate the percentage of delivered boluses that were self-
determined (i.e. the participant did not access the IPBC for a suggestion before delivering 
an insulin bolus) and how often the bolus waveform was changed. 
3.4 Results 
3.4.1 Participant characteristics 
There were 19 participants recruited; 7 employed CGMS and the remainder 
utilized capillary glucose monitoring (Paradigm System), with 13 participants using one 
or more BG meters that communicated with the IP.  Four IPs were used by the 
participants: 9 on MiniMed530G-551, 1 on MiniMed530G-751, 5 on ParadigmRevel-
523, and 4 on ParadigmRevel-723.  The average participant age was 48(15) years and the 
self-reported duration of T1D and duration of IP therapy was 27(13) and 11(5) years, 
respectively.  Mean HbA1c was 7.3(1.0). There was a higher percentage of recruited 
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women (63%) and most were white (95%). We analyzed an average of 32(4.8) days of 
data from each participant and a total of 4,249 interactions with the IPBC.  All data are 
reported as mean and standard deviation (SD).   
3.4.2 Daily minimally expected self-management behaviors 
Inter-subject variability to the three minimally expected daily behaviors was 
observed (Table 3.1: Observed frequency of investigator defined minimally expected 
daily behaviors, differentiating between the group of participants under capillary glucose 
monitoring and the group using CGMS.  Reported as mean (SD), range.).  Carbohydrates 
were entered into the IPBC 3 or more times per day an average of 76.6%(31.7%).  Levels 
of adherence were similar between those on CGMS and capillary glucose monitoring, 
84.0%(29.7%) and 72.3%(33.3%), respectively.  Five participants showed adherence to 
this behavior 100% of the time, while one participant showed a maximum of 2 
carbohydrate entries per day.  Carbohydrates were documented an average of 3.9(1.6) 
times per day.  
Participants delivered insulin boluses an expected 3 or more times per day an 
average 96.8%(5.7%).  There were 11 participants whose observed bolus adherence was 
100%; all but one participant achieved 90% or better adherence.  On average participants 
delivered an insulin bolus 7.5(3.6) times per day.  Although not statistically significant, 
participants on CGMS delivered an average of 9.4(4.8) boluses per day while participants 
using capillary glucose monitoring averaged 6.5(2.3) boluses per day.  
Adherence to glucose checks was similar for participants on CGMS when 
compared to those on capillary glucose monitoring even though providers at the Mayo 
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clinic advise patients on CGMS to calibrate with a capillary glucose check a minimum of 
2 times per day. On average, participants on CGMS checked BG 4.5(1.4) times per day 
and those on capillary glucose monitoring checked 4.2(2.5) times per day.  None of the 
participants were perfectly adherent to checking or recording BG and only 3 achieved 
90% or better adherence.  
When all three minimally expected behaviors were considered together 
participants were simultaneously adherent to all three investigator-defined guidelines on 
average 52.3%(34.3%) of days.  None of the participants were found to be 100% 
adherent and two individuals never engaged in the three recommendations 
simultaneously.  Adherence of all three behaviors between CGMS and capillary glucose 
monitoring was similar, 61.5%(32.9%) and 48.4%(35.5%), respectively.   
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Table 3.1: Observed frequency of investigator defined minimally expected daily 
behaviors, differentiating between the group of participants under capillary glucose 
monitoring and the group using CGMS.  Reported as mean (SD), range. 
BG Behavior 
Capillary Glucose 
Monitoring 
CGMS p-value 
Group 
Total 
Documented 
carbohydrates 3 or more 
times/day, % 
72.3 (33.3) 
0.0 – 100 
84.0 (29.7) 
17.2 – 100 
0.44 
76.6 (31.7) 
0.0 - 100 
Administered insulin 
bolus 3 or more 
times/day, % 
97.4 (5.6) 
80.6 – 100 
95.6 (6.2) 
82.8 - 100 
0.53 
96.8 (5.7) 
80.6 - 100 
Documented BG 4 or 
more times/day, % 
55.8 (36.1) 
0.0 – 94.4 
67.8 (26.4) 
37.9 – 96.4 
0.45 
60.0 (32.5) 
0.0 - 96.4 
All 3 behaviors/day, % 
48.4 (35.5) 
0.0 – 88.9 
61.5 (32.9) 
6.9 – 93.6 
0.43 
53.2 (34.3) 
0.0 - 93.5 
Documented 
carbohydrates/day, # 
3.8 (1.5) 
1.1 – 6.0 
4.2 (1.8) 
1.4 – 6.7 
0.62 
3.9 (1.6) 
1.1 – 6.7 
Administered insulin 
bolus/day, # 
6.5 (2.3) 
3.8 – 11.8 
9.4 (4.8) 
3.9 – 18.3 
0.17 
7.5 (3.6) 
3.8 – 18.3 
Documented BG/day, # 
4.2 (2.5) 
1.2 – 11.1 
4.5 (1.4) 
3.2 – 7.2 
0.72 
4.3 (2.1) 
1.2 – 11.1 
 
3.4.3 Relationship between daily minimally expected behaviors and glucose targets 
As depicted in Figure 3.1, when participants entered carbohydrates 3 or more 
times per day they achieved their individualized target BG in 4.6%(4.1%) of the recorded 
BG values during the 24-hours.  Days when that behavior was not observed the target BG 
was achieved 0.8%(1.7%).  When participants were observed bolusing 3 or more times 
per day it resulted in 5.2%(3.7%) BG readings at target, days when bolusing was less 
than 3 the target BG was recorded 0.1%(0.3%).  On days that participants checked BG 4 
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or more times per day they achieved target BG 3.5%(3.0%) versus 1.8%(3.3%) on days 
that expected behavior was not observed. When participants were adherent to all three 
minimally expected behaviors BG was at target 3.3%(3.0%), and 2.4%(3.2%) on days 
they failed to meet all three behaviors.  Although these findings were not significant 
(Fisher’s exact test), there was a high correlation between the observed frequency of 
behaviors and the percentage of BG readings that were at target.  Although not 
statistically significant, increasing the number of daily insulin boluses had the largest 
impact on increasing the number of BG readings at target for the day, r=0.93.  
Consuming carbohydrates and checking BG had correlation values of r=0.75 and r=0.53, 
respectively.  
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Figure 3.1: Comparison of blood glucose control for observed adherent/non-
adherent days based on investigator defined optimal behaviors and percentage of 
blood glucose readings at target for the day.  Along the x-axis are the behaviors of 
interest, while the y-axis the average of daily blood glucose readings at target on a 
scale of 0% to 10%. 
 
3.4.4 Daily insulin bolusing behaviors 
Table 3.2: Overview of the insulin pump bolus calculator (IPBC), insulin bolus 
decisions and additional information regarding the optimal behaviors.  Data reported as 
mean or % (SD), range. provides results for additional behaviors that were observed and 
analyzed.  Over the course of the month participants accessed the IPBC on average 
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198.7(94.3) times and insulin boluses were delivered 220.7(78.7) times during the same 
time period.  Two-thirds, 66.6%(16.1%), of the IPBC recommendations resulted from 
participants entering carbohydrates.  Correction BG readings were provided by 
participants in 74.8%(24.4%) of the IPBC recommendations.  Nine participants 
frequently entered BG corrections (>90%) while 4 participants entered BG corrections 
less than 50% of the time. 
Participants chose to deliver the same bolus amount as suggested by the IPBC in 
85.7%(12.7%) of delivered boluses (Table 3.2: Overview of the insulin pump bolus 
calculator (IPBC), insulin bolus decisions and additional information regarding the 
optimal behaviors.  Data reported as mean or % (SD), range.).  There were 8 participants 
who very often (>90%) chose the same bolus as the IPBC, while one participant chose a 
different bolus in 51% of the delivered boluses.  Participants were nearly even on their 
preference for choosing a larger or smaller bolus, 7.4%(6.1%) and 6.9%(9.3%), 
respectively.   
In 6.4%(10.8%) of the delivered boluses participants changed the waveform from 
normal to dual or square.  A majority of the participants (n=14) never or rarely (<5.0%) 
changed the bolus waveform while 3 participants changed the waveform in over 25% of 
the boluses they delivered. Participants occasionally chose to deliver an insulin bolus 
without consulting the IPBC, which constituted 13.0%(16.9%) of the delivered boluses.  
While 10 participants never or rarely (<5.0%) delivered an insulin bolus without 
consulting the IPBC, two participants delivered approximately 50% of their insulin 
boluses without accessing the IPBC.   
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Table 3.2: Overview of the insulin pump bolus calculator (IPBC), insulin bolus 
decisions and additional information regarding the optimal behaviors.  Data 
reported as mean or % (SD), range. 
Access IPBC Value 
IPBC recommendation provided, #  198.7 (94.3), 62 – 449 
BG control guidelines 
Carbohydrates entered to IPBC, %  66.6 (16.1), 38.8 – 100 
Boluses delivered, #  220.7 (78.7), 109 – 380 
BG entered to IPBC, %  74.8 (24.4), 35.8 – 100 
Bolus recommendations from IPBC 
Select same bolus suggested by IPBC, %  85.7 (12.7), 49.1 – 100 
Select larger bolus than suggested by IPBC, %   7.4 (6.1), 0.0 – 18.5 
Select smaller bolus than suggested by IPBC, %  6.9 (9.3), 0.0 – 32.7 
Other Bolus Decisions 
Select square or dual bolus waveform, %  6.4 (10.8), 0.0 – 30.4 
Bolus without consulting IPBC, %  13.0 (16.9), 0.0 - 52.7 
 
3.4.5 Monthly frequency of expected self-management behaviors 
In addition to the daily analysis of participant’s behavior (Table 3.1 & Table 3.2), 
we analyzed for each participant the monthly frequency of five distinct behaviors: 1) 
disregarding BG readings and only accounting for carbohydrates when using the IPBC, 
2) bolusing without consulting the IPBC, 3) changing the bolus waveform to dual/square, 
4) choosing insulin boluses different from those suggested by the IPBC, and 5) frequent 
bolusing: 4 or more boluses in a 5-hour time period or delivering 10 or more boluses 
during a 24-hour period.  As shown in Table 3.3: Categories of insulin compensation 
techniques observed in study participants, including: 1) disregarding BG readings and 
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only accounting for carbohydrates when using the IPBC, 2) bolusing without consulting 
the pump, 3) changing the insulin bolus delivery from waveform to square, 4) choosing 
insulin boluses different from those suggested by the IPBC, and 5) bolusing 4 or more 
times in a 5-hour period or delivering 10 or more boluses during a 24-hour period., we 
categorized each participant as never (0 events), rarely (1-4 events), occasionally (5-14 
events), regularly (15-90 events) or excessively (more than 90 events) showing a 
behavior over the course of one month.  
We observed that 15 participants occasionally or regularly chose a different 
insulin bolus than the one recommended by the IPBC and that 4 participants rarely or 
never chose a different bolus.  All the behaviors reported in Table 3.3 were automatically 
computed, except for the frequency of blousing which was manually counted on a subset 
of the participants: 7 on CGMS and 2 on capillary glucose monitoring.  Out of the subset 
of 9 participants, 3 occasionally or regularly bolused frequently while 6 rarely or never 
bloused frequently.   
Using the IPBC to adjust for meal’s carbohydrates while omitting a current BG 
reading was done regularly or excessively by 9 participants, while 9 rarely or never 
omitted a current BG reading and 1 occasionally did so.  Bolusing without consulting the 
IPBC was done regularly or excessively by 8 participants and 10 rarely or never delivered 
a bolus without the IPBC and 1 occasionally bolused without the IPBC.  There were 13 
participants that never or rarely changed the bolus waveform and 6 who regularly or 
excessively changed the bolus waveform. 
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There were some associations between insulin pump behaviors and patient 
profiles that emerged as well.  Compensating for carbohydrates without checking BG was 
negatively correlated with changing the waveform to square while selecting a different 
bolus was positively correlated with square waveform delivery.  There were four 
participants whose behaviors correlated inversely to the two patterns just mentioned, and 
these four participants had the highest frequency of delivering square waveform boluses.  
There were 10 participants that regularly or excessively omitted BG readings when using 
the insulin pump bolus calculator, and 7 of them never or rarely selected a different 
insulin bolus than suggested by the pump, while 6 of the remaining 9 participants 
occasionally or regularly selected a different bolus.  This pattern may arise from 
situations where participants are unaware of glucose trends or are unable to check 
glucose levels, and as such are less likely to override the IPBC when only compensating 
for carbohydrates. 
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Table 3.3: Categories of insulin compensation techniques observed in study 
participants, including: 1) disregarding BG readings and only accounting for 
carbohydrates when using the IPBC, 2) bolusing without consulting the pump, 3) 
changing the insulin bolus delivery from waveform to square, 4) choosing insulin 
boluses different from those suggested by the IPBC, and 5) bolusing 4 or more times 
in a 5-hour period or delivering 10 or more boluses during a 24-hour period. 
Behavior 
Never 
(0 events) 
Rarely 
(1-4 events) 
Occasionally 
(5-14 events) 
Regularly 
(15-90 
events) 
Excessively 
(90+ events) 
Compute carbs 
only (n=19) 
7 2 1 5 4 
Bolus without 
consulting pump 
(n=19) 
7 3 1 7 1 
Change waveform 
to dual/square 
(n=19) 
10 3 0 5 1 
Clinically 
different bolus 
selected (n=19) 
3 1 7 8 0 
Frequent boluses 
(n=9) 
4 2 2 1 0 
 
3.5 Discussion 
Diabetes behavior studies have mainly relied upon self-reported data gathered 
from interviews, surveys and questionnaires [76,80,84].  These methods have been used 
to gather qualitative data which contributes to the understanding of behavioral diabetes 
such as insights about the beliefs, motivations, perceptions and expectations of the patient 
which can be used to inform changes to therapy regimens that can improve adherence 
[85,86].  There are limitations to self-reported data such as recall bias (i.e. inaccurately 
remember and report behaviors) and social desirability (i.e. over-report favorable 
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behavior and under-report poor behavior).  White coat adherence may be a source of bias 
when measurement instruments are delivered during patient-provider encounters since 
patients may improve their SMB in the days or weeks leading up to the appointment 
[87,88].  In our case data was collected after the appointment with the provider and 
months before the next appointment. 
Although we were able to assess the adherence to diabetes management 
recommendations and other SMB by using device recorded data, this study was limited 
by a small sample size which lacked the power to detect differences between groups.  The 
demographics of this cohort may not be representative of the general T1D population 
based on race and HbA1c.  Another limitation of this study is that participants may have 
used one or more glucose meters that did not communicate with the IP and subsequently 
the use of those devices would not have been captured by the IP.   
Consistent with other studies, we found that there was variability of observed 
behaviors across participants and that there was a direct correlation between daily 
adherence to expected SMB and better glycemic control [76–80].  Although this cohort 
had an average of 11 years’ experience with IP therapy, advanced features, such as 
changing the bolus waveform to dual or square, were used infrequently. 
The ADA guidelines suggest that treatment regimens may be intensified if 
patients are adherent to their current regimen, or in the case of poor adherence the routine 
should be simplified in order to improve adherence [8].  Clinicians relying only on self-
reported assessments may overestimate patients’ adherence since it has been shown that 
patients who struggle with adherence are less likely to honestly report their deficiencies 
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in SMB [84,89]. While clinicians mainly rely on quantified data coming from diabetes 
technology, this type of data has limitations, too.  Actual behaviors may be different from 
what was documented in the IP.  For instance, a participant had a meal and delivered a 
bolus without entering carbohydrates and without requesting advice from the IPBC.  This 
may partially explain why the behavior with the highest frequency was delivering insulin 
boluses.  
In this study we found that increasing the frequency of insulin boluses, calculating 
carbohydrate consumption and checking BG had a positive impact on glycemic control 
with the delivery of insulin boluses having the greatest impact.  Providing real-time 
monitoring via the IP, or other appropriate device (e.g. smartphone app with wireless 
connection to IP) on these minimally expected behaviors could empower patients and 
improve daily diabetes self-management and glycemic control. 
For providers, presenting information gathered by IPs in ways that are clinically 
relevant and actionable could be empowering.  Availability of precise and complete BG 
data that is presented in a structured manner enables providers to more efficiently and 
accurately identify glucose patterns which can lead to more accurate therapeutic 
decisions [90–92].  Take for instance Table 3.3: Categories of insulin compensation 
techniques observed in study participants, including: 1) disregarding BG readings and 
only accounting for carbohydrates when using the IPBC, 2) bolusing without consulting 
the pump, 3) changing the insulin bolus delivery from waveform to square, 4) choosing 
insulin boluses different from those suggested by the IPBC, and 5) bolusing 4 or more 
times in a 5-hour period or delivering 10 or more boluses during a 24-hour period., where 
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we classified the frequency of five observed behaviors by monthly frequency (never, 
rarely, occasionally, regularly and excessively), instead of daily means and SDs (Table 
3.2). This way to visualize the data could help the clinician to better identify patients that 
behaved in a certain way more often or less often than the average patient. For instance, if 
during the last month the patient never changed the bolus waveform, the clinician could 
spend time during the next clinical encounter reviewing how to change the bolus delivery 
in the IP and discussing potential meal types that could benefit from a square insulin 
delivery to improve glycemic control. For the example of the patient who frequently 
boluses (15-90 monthly events when the patient delivers 10 insulin boluses per day or 
more than 5 boluses within 4 hours), the clinician can review the patient’s endocrine 
settings to identify if the basal rate needs to be changed to reduce frequency of insulin 
bolusing.  Even with the small number of participants we were able to identify 
associations between certain behaviors.  Identifying patient profiles based on similar 
behaviors could also be helpful in the design and implementation of interventions aimed 
at improving adherence.  It remains as an open question to understand which are the best 
ways to present patients’ diabetes SMB to providers to facilitate their decision process. 
3.6 Conclusion 
This study quantified observed SMB of adults on IP therapy by analyzing 
objectively recorded data from IPs. A limitation of our research is that we did not collect 
information on the reasons behind observed participants’ behaviors. Nevertheless, the 
results from this quantitative study show that the majority of the adult patients on insulin 
pump therapy in this study regularly seek guidance from the bolus calculator imbedded in 
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the insulin pump to dose preprandial insulin boluses as well as boluses to correct for out-
target glucose.  This study establishes that for meals and glucose excursions patients have 
adopted SMBs that incorporate technologies that provide decisional support as they self-
monitor glucose levels.   
In Chapter 2 we reviewed the Medtronic MiniMed, Inc. [28] bolus calculator and 
its intended use as specified by the manufacturer [28].  We also met with a diabetes 
education nurse to understand how patients with diabetes are trained to use the IPBC.  
This helped us to understand in theory how the IPBC has been designed to be 
incorporated in the self-management of diabetes.  In this study we were able to observe 
patients in real-life situations which helped us to understand how they actually integrate 
the IPBC into daily self-management routines.  The insight we gained from this study has 
proved to be very helpful as we have progressed with the design and development of the 
iDECIDE decision aid and incorporating it into the iDECIDE smartphone app. 
In Chapter 2 we also identified that current diabetes technologies do not 
incorporate exercise or alcohol, two lifestyle preferences known to affect glucose levels, 
into algorithms that suggest insulin bolus amounts. In the following chapter we 
conducted a study on how patients compensate for exercise and alcohol to further assess 
the need for decisional support tools that account for exercise and alcohol.   
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4 CHARACTERIZATION OF EXERCISE AND ALCOHOL SELF-
MANAGEMENT BEHAVIORS OF TYPE 1 DIABETES PATIENTS ON 
INSULIN PUMP THERAPY 
4.1 Introduction 
There is a lack of systematic ways to analyze how diabetes patient use their 
insulin pumps to self-manage blood glucose to compensate for alcohol ingestion and 
exercise.  This chapter uses qualitative and quantitative methods to better understand how 
patients on insulin pump therapy compensate for exercise and alcohol to maintain 
glycemic control (Aim 2). 
We recruited adults with type 1 diabetes (T1D) on insulin pump therapy to 
analyze “real life” insulin dosing decisions occurring in conjunction with alcohol intake 
and exercise.  Participants were asked to maintain their daily routines, including those 
related to exercising and consuming alcohol.  Participants kept a 30-day journal on the 
exercise they performed and the alcohol consumed which were later manually coded into 
tabular format.  Thirty days of corresponding insulin pump data were downloaded.  
Computer programs were written to automatically collate insulin pump and journal data.  
Each row in the journal data that contained an exercise or alcohol event was analyzed for 
its temporal relationships to participants’ actual insulin dosing behaviors as recorded by 
the insulin pump.  For example, the computer programs would scan for an exercise or 
alcohol event from the journal data and then identify if any compensation techniques (e.g. 
consume carbohydrates, check BG) occurred immediately before, during or after the 
exercise event.  In the collated data in Figure 4.1 there are two exercise events, the first 
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one was accompanied by blood glucose check, carbohydrates and an insulin bolus 21 
minutes after completion.  The participant also consumed carbohydrates and delivered an 
insulin bolus 22 minutes before consuming alcohol but did not check blood glucose 
levels. 
 
Figure 4.1: Paper logs were manually coded into tabular data and then were 
automatically merged with raw data from the insulin pump.  Each row of collated 
data was analyzed for temporal relationships between insulin pump behaviors and 
exercise and alcohol. 
 
Nineteen patients were recruited and over 4,000 interactions with the insulin 
pump were analyzed.  The analysis exposed variability in how subjects perceived the 
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effects of exercise and alcohol on their blood glucose, inconsistencies between self-
reported and observed behaviors, and higher rates of blood glucose control behaviors for 
exercise vs. alcohol.  These findings further validated the need to propose an insulin 
dosing algorithm that accounts for exercise and alcohol (Aim 3).   
The results from this research were first presented as a poster at the Diabetes 
Technology Meeting 2015 and then as a poster at the ADA 76th Scientific Session 2016 
[71,72] (APPENDIX A.2 and A.3).  Chapter sections 4.2 through 4.5 comprises the 
extended version of those posters which was published in the Journal of Diabetes Science 
and Technology [93] (APPENDIX C.2). 
4.2 Background 
While evidence shows that alcohol and exercise affect the absorption of insulin 
and increase the risk of hypoglycemia, there is a lack of evidence-based decision tools to 
allow for translation of this information into practice [11,13,15,16]. Patients with T1D 
must manage their disease by injecting insulin deliverable through syringes, insulin pens, 
or insulin pumps. Pre-meal insulin dosage compliance and accuracy is a key factor in 
achieving target postprandial glucose levels. Insulin pumps, being used in 2013 by over 
350,000 people in the US [94], incorporate proprietary mathematical algorithms called 
bolus calculators or bolus wizards to determine individualized pre-meal dosing 
[29,95,96]. The benefits achieved through the use of insulin pumps and continuous 
glucose monitors (CGM) are not necessarily a direct result of wearing the devices but 
rather due to behavioral and management changes enabled by the information provided 
by the devices to the users [95]. While bolus calculators and CGMs can lead to better 
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glucose control [7,10], bolus calculators currently cannot account for the lifestyle 
complexities of alcohol ingestion and planned exercise [12–14,17,97,98].  
Among adult T1D patients, little is known about patient self-management 
behaviors in the setting of alcohol intake and exercise.  A review of the literature 
demonstrated a lack of studies analyzing adult T1D patients’ self-reported behaviors 
against their actual behaviors documented from data collected by an insulin pump.  Better 
understanding of these behaviors could help in the design of educational programs, 
particularly as it relates to intensive insulin therapy, and aid in designing better dosing 
algorithms that account for behaviors related to alcohol consumption and exercise 
patterns. The aim of this study was to analyze adult T1D patients self-reported vs. actual 
self-management behaviors occurring in conjunction with alcohol intake and exercise. 
4.3 Methods and Materials 
4.3.1 Subject Recruitment 
After Institutional Review Board approvals 19 adult T1D patients were recruited 
from an academic outpatient endocrinology clinic. Participants were between the ages of 
18-70, non-pregnant, English speaking, who had been using an insulin pump from a 
single vendor for at least one year. Patients in fragile health, limited life expectancy, a 
history of mental health problems, advanced vascular disease or micro vascular 
complications and known history of severe hypoglycemia were excluded.  Study 
personnel identified potential subjects at the time of their scheduled outpatient visit. 
Subjects were handed a flyer that provided details on the study. 
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4.3.2 Data collection 
The study team conducted structured interviews to collect participants’ self- 
reported perceptions of how alcohol and exercise affected blood glucose levels and the 
sources of information used to learn about these interactions. Additionally, subjects were 
asked if they accounted for alcohol and exercise in their insulin dosing decisions, and 
what type of techniques they used to compensate for these behaviors (e.g. carbohydrate 
consumption, reduction in insulin bolus or basal rate, or some combination of these 
methods).   
Participants were asked to maintain their daily routine and to keep a journal on the 
time, duration and intensity of exercise performed (e.g. at 9:00 a.m. performed 20 
minutes of high intensity exercise) and the time, type and amount of alcohol consumed 
(e.g. at 10:20 p.m. drank a can of light beer) for 4 consecutive weeks. Patient’s recorded 
how they compensated for alcohol and exercise on the logs. Participants were called once 
during the study to assess progress and answer questions. At the end of the data collection 
period, patients mailed or faxed in their completed alcohol and exercise logs. 
The study team also obtained the data contained within the participants’ insulin 
pump during the same 4-week period. The patients uploaded the insulin pump data 
through a website provided by the insulin pump’s manufacturer, which was remotely 
accessed by study personnel. Once the data was downloaded the patients were 
encouraged to change their passwords. Alternatively, patients could meet in person with a 
member of the study team who could download the data from the patient’s insulin pump.  
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4.3.3 Data analysis 
Subjects’ perceptions of the effect of alcohol and exercise on glucose levels and 
their sources of information regarding alcohol and exercise were tabulated. Data from the 
paper-based diaries were electronically coded and analyzed to quantify for each study 
participant number of drinks and frequency of exercise. To report patients’ observed 
behaviors for exercise and alcohol we reviewed data downloaded from the insulin pumps 
and from the participants’ paper-based diaries to quantify how often patients used 
techniques to compensate for alcohol ingestion and exercise activity, such as adjusting 
insulin (basal rate or bolus) or taking snack within 30 minutes before exercising. 
Computer algorithms were written to associate self-reported days and times of alcohol 
consumption and exercise to the corresponding data collected by the insulin pumps. 
Using the aggregated data, the frequency of compensation techniques related to 
carbohydrate consumption, insulin boluses delivered, and blood glucose monitoring 
occurring in close temporal proximity to exercise or alcohol consumption was computed 
for each study participant. Close temporal proximity was defined as ±30 minutes of 
alcohol consumption or exercises.  
4.4 Results 
4.4.1 Demographics 
Nineteen subjects with T1D were recruited. Mean (SD) age was 48 (15) years, 12 
were women, and 18 were of white race. Mean (SD) hemoglobin A1c was 7.3 (1.0)%, 
self-reported duration of diabetes was 27 (13) years, and duration of insulin pump therapy 
was 11 (5) years. Seven participants wore a CGMS, and the remaining used capillary 
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glucose monitoring. There were 4,249 interactions between the study participants with 
the insulin pump bolus calculator analyzed. There were 347 exercise events recorded by 
17 participants and 155 alcohol events recorded by 11 participants.  
4.4.2 Perceived interactions and sources of alcohol and exercise information 
When subjects were asked about how alcohol or exercise impacted their glucose 
control, there were no consistent responses observed (Table 4.1).  There were 7 
participants who all stated that exercise lowers blood sugar, another 7 whose responses 
varied on how glucose reacted to exercise, and another 5 without responses. With respect 
to alcohol (Table 4.1), 8 participants stated that their reactions to alcohol depended on 
factors like the number of drinks (e.g. only compensating when consuming 2 or more 
drinks) or type of drinks (e.g. differentiating between drinks with high or low alcohol 
concentration), 1 who stated there was no effect on glucose, 2 who did not know, and 8 
who did not respond. 
Participants also reported deriving information on how exercise and alcohol 
affected their blood glucose from a number of different sources (Table 4.2). Most 
participants indicated they learned about the interactions from trial and error and had 
developed their own heuristics. Few participants reported having received information or 
education from providers on approaches to compensate for alcohol or exercise when self-
managing blood glucose. Two participants indicated that they would like to receive more 
information on the way alcohol affects blood glucose. 
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Table 4.1: Subject perceptions on how exercise and alcohol affect blood glucose. 
Activity 
No. of 
subjects 
Perception Sample comments 
Exercise 
7 It lowers blood glucose 
“In the past, drinking causes low 
blood glucose overnight” 
7 
 
Various effects, based on 
type of activity, intensity 
and time of day 
“Interval training elevates or lowers 
blood glucose, backpacking raises 
it” 
“The effect depends on the time of 
day and the type of exercise” 
“Exercise may not drop blood 
glucose” 
“Morning exercise raises the blood 
glucose, but evening exercise lowers 
it” 
5 No reported data  
Alcohol 
8 
Various effects, based on 
number of drinks and 
drink type  
“Alcohol raises blood glucose 
initially and lower it hours later”  
“Beer raises blood sugar” 
“I feel I have to take insulin if I 
have beer, but no insulin if I have 
hard alcohol” 
“Almost always raises it” 
“If I have more than a few drinks 
the blood glucose lowers, if I have 
hard alcohol it raises and then 
lowers” 
1 
No effect or minimal 
effect 
“I don’t see much effect” 
2 Lack of knowledge 
“I don’t know; I need more 
information” 
8 No reported data or N/A “I don’t drink” 
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Table 4.2: Subject self-reported sources of education on how exercise and alcohol 
affect their blood glucose. 
Activity No. of subjects Source of education 
Exercise 
19 Trial and error 
2 Literature/online reading 
2 Provider education 
1 Other diabetes patients 
Alcohol 
12 Trial and error 
3 Literature/online reading 
1 Provider education 
5 Other diabetes patients 
4 N/A 
 
4.4.3 Overall self-management behaviors 
Current American Diabetes Association (ADA) Standards of Care Guidelines 
suggest that patients should consider checking blood glucose prior to exercise and 
recommend that in order to avoid hypoglycemia the insulin dose and/or carbohydrate 
intake may need to be altered [8].  Many health care organizations suggest that alcohol 
should be consumed with a meal containing carbohydrates in order to avoid 
hypoglycemia [98–100]. Data entered into the subjects’ insulin pumps indicated self-
management techniques did not match current recommendations (Figure 4.1). When 
comparing self-management techniques for exercise versus alcohol, participants 
consumed carbohydrates (40.9% vs. 20.6%), delivered an insulin bolus (38.3% vs. 
26.8%), or checked their blood glucose (60.7% vs. 27.3%) more consistently with 
exercised than when consuming alcohol. 
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Similar to [76], study participants’ adherence to ADA recommendations for 
alcohol consumption and exercise were quantified [8]. According to the guidelines 
“adults with diabetes should be advised to perform at least 150 min/ week of moderate-
intensity aerobic physical activity (50–70% of maximum heart rate), spread over at least 
3 days/week with no more than 2 consecutive days without exercise”. Weekly adherence 
to this guideline by study participants was 38.4% (45.4), with 5/17 subjects reporting 
100% adherence and 10/17 subjects at 0%. The ADA also recommends “adults with 
diabetes who drink alcohol should do so in moderation (no more than one drink per day 
for adult women and no more than two drinks per day for adult men)”. Adherence to the 
ADA guidelines for daily alcohol moderation was 94.6% (9.2) within the range of 70 to 
100. 
 
Figure 4.2: A) Carbohydrate intake, B) Insulin bolusing and C) Blood glucose 
checking within ±30 minutes of exercise or alcohol consumption. For instance, as 
depicted in A) in temporal proximity of alcohol events subjects consumed carbs with 
20.6% mean, 15.3% standard deviation, and 0-42.9% range. In contrast, in 
proximity to exercise events subjects consumed carbs with 40.9% mean, 25.5% 
standard deviation and 0-93.3% range. 
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4.4.4 Observed versus actual behaviors associated with exercise and alcohol 
Next, we contrasted subjects reported self-management techniques against 
observed behaviors for exercise and alcohol, as derived from analysis of corresponding 
data contained with the subjects’ insulin pumps. Self-described compensatory self-
management techniques to compensate for exercise and alcohol consumption were 
categorized as: no compensation, adjusting insulin (reducing basal rates or boluses), 
ingesting snacks, or removing the pump. When examining behaviors related to exercise, 
discordance was seen between what subjects claimed they did versus actual behavior. For 
instance, 16 subjects reported they would adjust insulin pump settings when exercising, 
while only 7 were observed to have done so (Table 4.3). Another 2 indicated they would 
take a snack, but 5 were noted to employ this technique. While 2 study participants 
reported always adjusting basal insulin, no patients were observed always adjusting their 
basal settings.  Although 2 patients reported sometimes removing the pump during 
exercise, the pump disconnection was not explicitly recorded in the insulin pump data we 
had access to, hence we were not able to quantify this behavior.  
Similar discrepancies were noted between what subjects said they would do and 
what they actually did when reviewing self-management behaviors related to alcohol 
ingestion (Table 4.3). For example, 5 subjects indicated they would not compensate for 
alcohol use, while 8 were actually observed not making any adjustments.  There were 10 
subjects who indicated they would adjust insulin when drinking alcohol, but only 3 were 
noted to have done so. 
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Table 4.3: Patient self-reported compensation techniques and observed behaviros 
for exercise and alcohol. 
 
Activity Compensation 
technique 
Comments No. of 
subjects 
reported 
using the 
technique 
No. of 
subjects 
who used 
the 
technique 
Exercise No compensation  1 1 
Adjust insulin 
(basal rate or 
bolus) sometimes 
or always 
 
“When I perform 
strenuous exercise I 
reduce basal rate” 
“When I play hockey I 
take a bolus of 1 ½ unit, 
then I remove the pump” 
“When involved in 
anaerobic exercise I take 
insulin, if it is aerobic 
exercise I don’t take 
insulin” 
16 7 
Remove pump “Sometimes I remove 
my pump” 
2 0 
When needed, take 
snack before 
exercising 
“If my blood sugar is 
less than 200 in the 
evening I eat a snack or 
I reduce the basal rate to 
half and I get to 100.” 
2 5 
No data  2 9 
Alcohol No compensation  5 8 
Adjust insulin by 
compute drinks’ 
carbs, sometimes 
or always 
 
“I was told by my 
endocrinologist to not 
compute drinks’ carbs 
when I take 1 or 2, 
otherwise yes” 
“I feel I have to take 
insulin when I drink 
beer but no insulin when 
I drink hard alcohol”  
10 
 
3 
No data or NA “I don’t drink” 4 8 
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4.5 Discussion 
Qualitative studies of children, adolescent, and adult diabetes patients have been 
performed with the purpose of understanding behavioral diabetes care [76,77,80,85,101]. 
While in general qualitative studies are limited by small sample sizes and do not generate 
statistically significant data, their findings are crucial to give a glimpse into patients’ 
beliefs, attitudes, behaviors, culture and lifestyle. With diabetes in particular, 
understanding patients’ behaviors is very important to discover the reasons behind non-
adherence to treatment or poor glycemic control, and to identify the best ways to deliver 
effective interventions. 
With respect to self-care, qualitative studies have shown that many patients lack 
understanding of how medications, food, and exercise affect blood glucose control and 
what kind of information needs to be taken into account (carbohydrate content of food, 
activity level, etc.) to self-manage diabetes effectively [102,103]. In terms of physical 
activity, the qualitative study by Hendricks et al. interviewed forty nine emerging adults 
(18 to 26 years old) to understand their exercise habits and to determine their compliance 
with the ADA recommendations on physical activity [76]. The ADA recommends at least 
30 minutes of daily physical activity for youth. In Hendricks, et. al. study 41% of 
participants engaged in exercise at least once daily; 55% of those individuals who 
engaged in daily exercise demonstrated a mean duration of 30 minutes or more. Mean 
exercise duration was 29.56 minutes/day and ranged from 0 to 157 minutes.  
To eliminate inaccuracies from self-reported data and to obtain statistically 
significant results by increasing the sample sizes, quantitative studies are taking full 
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advantage of the data generated by diabetes technology as was conducted here. Blood 
glucose monitors, continuous glucose monitors and insulin pumps can objectively store 
data that reflects what patients actually do, as opposed to what patients say they are doing 
(self-reported data). Driscoll and Young-Hyman provide a detailed review of the use of 
such technology in assessing adherence to diabetes self-management behaviors [70]. 
Their 2014 review focused on patients’ adherence to the ADA Clinical Practice 
Recommendations with an emphasis on studies that assessed patient adherence to glucose 
monitoring, insulin administration, medical nutrition therapy, and physical activity [104]. 
The review by Driscoll and Young-Hyman did not discuss alcohol consumption. In terms 
of physical activity, their review highlighted the lack of studies that quantify physical 
activity and suggest the future use of accelerometers to objectively measure physical 
activity. 
The goal of this study was to address the lack of qualitative and quantitative 
studies to understand adult T1D patients’ self-management practices occurring in 
conjunction with alcohol intake and exercise. Results indicated that subjects did not have 
a consistent understanding of how exercise and alcohol affected their glucose control, nor 
did they report a common set of standards on how they compensated for the impact of 
these common lifestyle choices in their diabetes management. Additionally, there was no 
one means by which they obtained information on these important topics. Documented 
adjustments in carbohydrate intake, insulin doses, and glucose monitoring occurred at 
frequencies lower than what might be expected. In the case of alcohol consumption, very 
few instances of changes in self-management behavior were noted.  
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The results demonstrate the need for a revision of current educational strategies to 
help patients understand proper alcohol and exercise compensation techniques and to 
encourage consistent behaviors. A number of approaches could be utilized, such as the 
use of social media, or incorporating more consistent or complete training during diabetes 
self-management education sessions. Another approach could be the development of 
software applications that assist patients in making decisions about how to change 
carbohydrate intake or adjust insulin doses in the event of an exercise or alcohol event.  
Further research will be needed to better understand and explain the findings 
observed here and their practical implications. This study revealed that many patients 
described using a behavioral technique that was inconsistent with their actual behaviors. 
While it is clear that subjects were often acting in a manner different than that reported, it 
is unclear if these study subjects were conscious of these inconsistencies. Future work 
could aim to better understand real life insulin pump behaviors and look for explanations 
for observed behaviors from study participants by re-contacting and interviewing them 
using sets of detailed scenario-based questions that replicate the most frequently observed 
behaviors.  It would also be interesting to review patient data with the subjects to see if 
they were aware of their inconsistencies. Similar detailed scenario-based questions that 
could help to understand reasons for patients’ common self-management behaviors could 
be posted to diabetes patients online communities, like Glu (https://myglu.org) or 
PatientsLikeMe (https://www.patientslikeme.com), that are designed to accelerate 
research and amplify the collective voice of thousands of diabetes patients. 
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An important limitation of our study was the use of paper-based records for 
collecting participant’s self-reported data on exercise, alcohol and carbohydrate intake. It 
is possible that subjects were not recording all their exercise or alcohol events. There are 
methods available to improve upon the accuracy of the data collected that are currently 
being employed in a follow-up study currently underway. For instance, to achieve higher 
accuracy in the reported data on exercise wristband heart rate accelerometers are being 
provided to subjects that measure the intensity and duration of exercise. In this follow-up 
study, participants are being asked to use a smartphone app to self-report data on 
perceptions on how alcohol/exercise affect insulin absorption and sources of education, 
and food and alcohol consumed and exercise performed.  The authors expect to take 
advantage of the ubiquity of smartphones to obtain more precise records on food and 
alcohol consumed and exercise performed. Another limitation is the small sample size, 
although each subject did generate multiple behaviors that could be analyzed. 
4.6 Conclusion 
The reported analysis of real life diabetes self-management decisions provided 
insight on behaviors occurring in conjunction with alcohol intake and exercise among 
patients using insulin pump therapy. The results of this study revealed the need for 
improved individualized educational techniques and decision support systems to assist 
patients with incorporating exercise and alcohol into daily life and self-management of 
their blood glucose.  The lessons learned from this study reinforces the need for a 
decision support tool, like iDECIDE, that accounts not only for meals, but also exercise 
and alcohol when making insulin bolus suggestions.  
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5 EVIDENCE-BASED INSULIN BOLUS DOSING ALGORITHM: IDECIDE 
5.1 Introduction 
In Chapter 2 we reviewed the state of the art on clinical evidence on lifestyle 
factors that affect diabetes patients’ blood glucose control, and decision support tools 
available to help patients self-manage blood glucose control (Aim 1). Our review 
indicates that while clinical evidence shows that carbohydrates, alcohol and exercise 
affect blood glucose control, current diabetes technology only account for carbohydrates 
when recommending insulin dosing.  Chapter 3 helped us to better understand how 
patients with diabetes use insulin pumps to daily manage their blood glucose and how 
they compensate for lifestyle choices when they are away from their endocrinologist 
(Aim 2).  The results presented in Chapter 4 showed that subjects did not have a 
consistent understanding of how exercise and alcohol affected their glucose control, nor 
did they report a common set of standards on how they compensated for the impact of 
these common lifestyle choices in their diabetes management (Aim 2).  These findings 
further validated the need to propose an insulin dosing bolus decision aid that accounts 
for exercise and alcohol.  Here we propose iDECIDE, an evidence-based insulin dosing 
decision aid (Aim 3). 
5.2 Background 
Current decision aids available to diabetes patients, such as bolus calculators 
embedded into insulin pumps, consider blood glucose, active insulin, and carbohydrate 
loads when making insulin recommendations.  Exercise and alcohol are two lifestyle 
preferences known to have an effect on blood glucose.  Reference Chapter 2.4.1-2.4.4 for 
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additional information regarding the effects of carbohydrates, insulin, exercise and 
alcohol on blood glucose. Reference Chapter 2.4.5-2.4.6 for an expanded background on 
the state of the art decision support systems for diabetes management.   
The objective was to adapt the standard insulin bolus equation (Equation 2.1) to 
account for exercise and alcohol in order to make recommendations that improve glucose 
control which are based on evidence identified in the literature review conducted in 
Chapter 2 (Aim 1). 
5.3 Methods and Materials 
Evidence regarding the effects of exercise and alcohol were identified in a 
literature search, see Chapter 2.3 for literature review methods.  The results of the 
literature review with regards to exercise and alcohol were briefly presented in Chapter 
2.4.3-2.4.4 (Aim 1).  The findings from the literature review were used to expand the 
standard insulin bolus equation (Equation 2.1) in order to account for exercise and 
alcohol. 
5.4 Results 
We propose a new insulin dosing equation (Equation 5.1) that builds upon the 
standard insulin blousing equation (Equation 2.1). As we noted previously, insulin pump 
calculators do not consider exercise when calculating insulin dosage, neither do they 
factor in the effects of carbohydrates in alcoholic beverages (alcohol carbs).  The 
proposed algorithm incorporates these two additional factors to suggest the dosage of 
rapid acting insulin or the consumption of carbohydrates.  In the following subsections, 
we describe the components of the iDECIDE insulin dosing bolus calculator.  
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Equation 5.1: Proposed insulin dosing equation to account for exercise and alcohol 
carbs: 
𝑈 = (
𝑐𝑎𝑟𝑏𝑠 + 𝑎𝑙𝑐𝑜ℎ𝑜𝑙 𝑐𝑎𝑟𝑏𝑠
𝐼𝐶𝑅
+  
𝑐𝐵𝐺 − 𝑡𝐵𝐺
𝐶𝐹
− 𝐼𝑂𝐵) − 𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒 
If U ≤ 0 then carbs = exercise 
5.4.1 Accounting for carbohydrates in meals 
A preprandial insulin bolus is delivered in order to account for the carbohydrate 
load in meals.  The amount of carbohydrates that 1 unit of insulin will cover is the insulin 
to carbohydrate ratio (ICR).  The amount of carbohydrates to be consumed is divided by 
the ICR in order to determine the amount of insulin bolus to deliver, represented by U, 
which represents the units of insulin. 
5.4.2 Accounting of out-of-range blood glucose 
When the target blood glucose range is set (tBG), the insulin sensitivity factor 
(ISF), or correction factor (CF), is used to determine the amount of insulin to compensate 
for a current blood glucose (cBG) which may be out-of-range.  The CF is the ratio of how 
much 1 unit of fast-acting insulin will lower blood glucose over the course of 2-4 hours 
during a fasting of pre-meal state.  When a range of target blood glucose is provided, 
iDECIDE will correct to the nearest target value when the current blood glucose is out or 
range. 
5.4.3 Accounting for insulin on board 
Insulin on board (IOB) is calculated to determine the amount of insulin still 
available in the blood stream to present “insulin stacking” which can lead to 
hypoglycemia.  We adapted the insulin concentration as reported by Lindholm, et. al. as 
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free serum insulin [105].  Table 5.1 shows the functions that were extrapolated from the 
Lindholm study and Figure 5.1 depicts the resulting linear function.  The calculation of 
IOB considers the area under the linear function by integration which results in 212.52 
mU/L of free serum insulin. The calculation for IOB is aggregate, so for example if 2.5 
hours had elapsed from the injection of 3 units of insulin the area under this portion of 
curve would be 157.24 mU/L, which is (157.24/212.52) = 74% of the area, or 74% of the 
insulin would be absorbed.  The IOB would be (3 * 0.74) = 0.78 units of insulin. 
Table 5.1: Time based calculations for insulin on board, where x is the time in hours 
following the delivery of an insulin bolus and y is the insulin amount in units. 
x y 
x = 0.00 to x <= 0.33 181.82 x 
x > 0.33 to x <= 0.49 38.0 + 67.0 x 
x > 0.49 to x <= 0.65 60.5 + 21.5 x 
x > 0.65 to x <= 2.50 88.5 – 21.5 x 
x > 2.50 to x <= 4.00 65.0 – 12.0 x 
x > 4.00 to x <= 6.00 50.5 – 8.42 x 
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Figure 5.1: Linear function that results from the function shown in Table 5.1, which 
were extrapolated from Lindholm, et.al. [105]. 
 
5.4.4 Accounting for carbohydrates in alcoholic beverages 
Studies done by Koivisto, et.al. and Gin, et.al. show that alcohol does not lead to 
hypoglycemia when the alcoholic beverage served was red wine, a beverage that contains 
carbohydrates [43,45].  Richardson, et.al. and Turner et.al. served alcoholic beverages 
with little to no additional carbohydrates and found that blood glucose levels were an 
average 50 mg/dL lower than when identical meals were served with water [17,44].  This 
leads us to consider that the carbohydrates associated with the alcoholic beverage may 
play a role in blood glucose levels and we chose to account for them when calculating 
insulin boluses.  
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We reviewed the alcoholic and carbohydrate content of the standard drink size of 
various beverages and grouped the drinks into the following five categories as depicted in 
Figure 5.2: Five classes of alcoholic beverages based on the carbohydrate and alcoholic 
content of one standard serving size. 1) spirits, 2) red wine, 3) light beer, white wine or 
cocktails, 4) beer or fortified wine, and 5) hard cider or mixed drinks.  These categories 
are used to determine the amount of carbohydrates associated with alcoholic beverages 
which allows the carbohydrates to be accounted for when calculating an insulin bolus 
which is reflected in Equation 5.1 (alcohol carbs). 
  
67 
 
 
Figure 5.2: Five classes of alcoholic beverages based on the carbohydrate and 
alcoholic content of one standard serving size. 
 
5.4.5 Accounting for exercise 
In the case of exercise, the algorithm can suggest an insulin bolus or to consume 
carbohydrates.  After carbohydrates (carbs/ICR), including those from alcohol (alcohol 
carbs/ICR), out-of-target blood glucose (cBG – tBG/CF) and IOB are considered in 
Equation 5.1, the combination of intensity and duration provides a reduction of the 
insulin bolus, see Table 5.2 [30].  If the calculation results in a positive amount of insulin 
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then insulin is suggested, if the calculation results in no insulin or a negative amount of 
insulin then the body weight of the individual is considered along with the intensity and 
duration of the exercise to suggest consuming a snack with carbohydrates.  See Table 5.3 
for the carbohydrate replacement values for every 30 minute increment of exercise [30].  
In order to use the carbohydrate replacement lookup table, we specified the weight ranges 
that map to the weight categories, see Table 5.4 
Table 5.2: Insulin reduction based on exercise duration and intensity. 
Exercise Intensity 
Short Duration 
(20-40 min) 
Moderate Duration 
(40-60 min) 
Long Duration 
(>60 min) 
Light -10% -20% -30% 
Moderate -25% -33% -50% 
Vigorous -33% -50% -67% 
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Table 5.3: Carbohydrate suggestion in grams for every 30 minutes of exercise, based 
on body weight and exercise intensity. 
Exercise Intensity 23 kg 45 kg 68 kg 91 kg 114 kg 
Light 3g 5g 8g 10g 12g 
Moderate 5g 8g 10g 12g 15g 
Vigorous 8g 12g 18g 24g 30g 
 
Table 5.4: Weight ranges for using Table 5.3.  
Weight Category Weight Ranges 
23 kg Weight <= 34 kg 
45 kg 34 kg < Weight <= 56 kg 
68 kg 56 kg < Weight <= 79 kg 
91 kg 79 kg < Weight <= 102 kg 
114 kg Weight > 102 kg 
 
5.5 Discussion 
We proposed an insulin dosing bolus calculator, iDECIDE, that not only accounts 
for standard variables, such as carbohydrates from meals and current blood glucose, but 
also considers exercise and alcohol, two factors that influence glycemic outcomes (Aim 
3).  One of the limitations of the proposed algorithm is that in its current form it only 
accounts for the acute effects of exercise and alcohol, although both are known to also 
have delayed effects on glucose levels [11,44].  One of the advantages of the iDECIDE 
algorithm is that it is based on clinical evidence that can easily be accessed by clinicians 
and patients, unlike closed-loop algorithms that use proprietary formulas and techniques 
such as machine learning that hide the rationality behind proposed recommendations.  
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Also, recommendations from iDECIDE can be broken down by each component of the 
equation to provide the reasoning for the insulin of carbohydrate suggestion. As more 
studies come forward, the iDECIDE decision aid can be adjusted to account for the latest 
evidence available.  
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6 A NOVEL METHODOLOGY TO COMPARE INSULIN DOSING ALGORITHMS 
IN REAL-LIFE SETTINGS 
6.1 Introduction 
In Chapter 5 we proposed the iDECIDE evidence-based decision aid (Aim 3) to 
recommend an insulin bolus dosage or carbohydrate intake, by taking into account 
relevant input on planned carbohydrate consumption from meals and alcohol, and 
intensity and duration of exercise.  Once the decision aid was developed it became 
necessary to assess its effectiveness to achieve blood glucose control, prior to its 
implementation as part of a smartphone application and dissemination to patients and 
providers for clinical use (Aim 4). 
Typically, clinical trials are used to determine the safety and efficacy of an 
intervention.  Clinical trials are prospective studies that require a significant amount of 
resources and expose patients to risks.  We found that there was a lack of low-cost and 
risk-free methods to retrospectively assess the performance of insulin bolus algorithms in 
preparation for future clinical trials.  Therefore, in this chapter we introduce novel 
methods to retrospectively: 1) compare the appropriateness of insulin bolus suggestions 
from bolus calculator that was prospectively applied in a real-life setting against a 
retrospective recommendation from a proposed bolus calculator, and 2) determine the 
appropriateness of a proposed insulin bolus calculator in cases where there are no 
recommendations from the conventional approach to compare against. 
Later, in Chapter 7, we applied the proposed methods to assess the effectiveness 
of iDECIDE’s recommendations and share lessons learned from collecting, aggregating 
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and analyzing real-life data generated by insulin pumps and self-reported patient 
behaviors. 
Preliminary results from this research were presented as posters at the Diabetes 
Science and Technology Meeting 2015 and the American Diabetes Association 76th 
Scientific Session 2016 [83,106] (APPENDIX A.3 and A.5).  An extended version of 
those posters has been published in the Journal of Diabetes Science and Technology 
[107] (APPENDIX C.3).  Chapter sections 6.2 through 6.3 comprise the portions of the 
published manuscript that introduce the novel method.  The remaining portions of the 
published manuscript are presented in Chapter 7. 
6.2 Background 
Models exist to study insulin delivery algorithms in controlled, simulated settings. 
Before undergoing clinical trials, a common practice to facilitate the design, development 
and testing of diabetes technology is to use in-silico methods [108–113].  Recently, 
Wong et al. proposed a method to retrospectively compare insulin bolus (IB) algorithms 
using Intensive Care Unit (ICU) data [114].  They concluded that in-silico comparisons 
appear to be an efficient nonclinical method for allowing rapid and inexpensive 
identification of computer-based protocols that justify expensive and burdensome clinical 
trials.   
Although algorithms exist to study IB algorithms in controlled environments, 
there is a lack of methods capable of analyzing glucose data simultaneously with patient 
behaviors and the goals was to develop an analytic method to retrospectively compare 
prandial IB recommendations. 
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6.3 Methods and Materials 
6.3.1 Retrospective comparison of two insulin bolus algorithms 
To evaluate the performance of the PDA against conventional approaches to 
prandial insulin dosing, the authors adapted methodology from Wong et. al. [114]. For 
this study, the conventional approaches to insulin dosing were defined as either use of the 
IPBC or participant’s self-determined doses. The PDA’s recommendations were 
compared against those made by the participant’s IPBC, or against the participant when 
they either overrode or neglected to get advice from their IPBC (Figure 6.1) 
The “appropriateness” of an IB was defined as one that brings the postprandial 
glucose to the desired target [114]. The method assumes that a conventional insulin 
dosing calculator, BCa (i.e. IPBC or the participant), has made an IB recommendation. 
The point in time when BCa made the IB suggestion and when the insulin was delivered 
is referred to as the initial time, ti. The method assumes that a proposed insulin dosing 
calculator, BCp (e.g. PDA), is retrospectively executed at the same data point, ti, to 
compare at time ti+1 the effect on BG of the insulin suggestion from BCp against the 
actual suggestion that was made by BCa. We considered that one calculator 
“outperformed” another calculator if there was a major performance enhancement over 
the competitor. For instance, in the case of a low postprandial BG we consider that a 
lower insulin dose recommendation outperformed higher insulin dose advice, potentially 
avoiding a hypoglycemic event. 
Applying this methodology requires that each preprandial BG at ti can be paired 
with a corresponding postprandial BG at ti+1. For meal events and BG corrections, we 
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defined ti+1 to be the first BG reading obtained 3 hours ±15 minutes, after ti. This time 
frame was chosen considering that the majority of the carbohydrate load and the rapid 
acting insulin analog bolus would have been absorbed and BG levels would have 
stabilized [105].  The BG readings at ti+1 were broken into three categories, based on pre-
determined individual target BG levels obtained from the insulin pump settings of each 
participant. The analysis determines which algorithm provided at time ti an IB 
recommendation that would have placed the participant closer to their target BG based on 
the category of the actual BG reading at ti+1. In the case of a target postprandial BG 
reading, we considered that a smaller insulin recommendation outperforms a larger 
recommendation because it could have avoided a hypoglycemic event. 
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Figure 6.1: Method used to retrospectively compare recommendations from two 
insulin bolus dosing algorithms, BCa and BCp.  If the recommendations from BCa 
and BCp were within 10% of each other they were considered to be equivalent. If 
the BG at ti+1 was low, then the smaller of the two recommendations from BCa and 
BCp was considered appropriate; if they were equivalent then neither was 
considered appropriate. If the BG at ti+1 was at target, then the smaller of the two 
recommendations from BCa and BCp was defined as appropriate, preferring 
recommendations that could avoid hypoglycemic events; if they were equivalent 
then both were considered appropriate. If the BG at ti+1 was above target, then the 
larger of the two recommendations from BCa and BCp was deemed appropriate; if 
they were equivalent then neither was considered appropriate. We considered that 
one algorithm outperformed the other if there was a major performance 
enhancement over competitor algorithm. In the case of on target postprandial BG, 
we consider that a lower insulin dose recommendation outperformed higher insulin 
dosing advice, potentially avoiding a hypoglycemic event.   
 
The method outlined in Figure 6.1 was used to compare the appropriateness of 
two calculators, BCa and BCp, and assumes that BCa (IPBC) has made IB 
recommendations that were delivered to the patient. A variation of that method is needed 
to assess the appropriateness of recommendations from BCp (PDA) when there is no 
available data from BCa (ie, no recommendation from the IPBC).  
6.3.2 Assessing the appropriateness of an insulin bolus algorithm for alcohol and 
exercise 
Conventional IPBCs do not provide IB recommendations for alcohol.  For these 
cases the method explained in Figure 6.2 was adopted. The postprandial time frame of 
interest, ti+1, was defined as the first BG reading obtained within 3 hours ±15 minutes. 
This time-frame neglects to consider any delayed effects from alcohol induced 
hypoglycemia and primarily focuses on the carbohydrates associated with alcoholic 
beverages.  
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Figure 6.2: Method used for assessing the appropriateness of the recommendations 
from the proposed decision aid (PDA), when patients choose to consume alcohol, for 
which the IPBC does not provide insulin dosing recommendations.  If the BG at ti+1 
is low or at target and the PDA did not recommend insulin the recommendation 
from the PDA was appropriate; if the PDA recommended insulin the 
recommendation was not considered appropriate. If the BG at ti+1 is high and the 
PDA recommended insulin the recommendation from the PDA was appropriate; if 
the PDA did not recommend insulin the recommendation was not considered 
appropriate. Given that our PDA is not compared against another calculator, 
outperformance is not defined. 
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As with alcohol ingestion, when participants exercised there were no 
recommendations made by the IPBC. For those cases, we used the method in Figure 6.3. 
We modified the window of ti+1 to be the first BG reading within 15 minutes of finishing 
exercise as recorded by the participant to detect any immediate effects of exercise-
induced hypoglycemia. For example, if the participant finished exercising at 8:30 AM, we 
used the first available BG between 8:30 and 8:45 AM. In the case of exercise, the PDA’s 
recommendations could be a carbohydrate snack in addition to an IB dose. For exercise 
scenarios, the appropriateness of the IB and/or carbohydrate was defined as in Figure 6.3  
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Figure 6.3: Method used for assessing the appropriateness of the recommendations 
from the proposed decision aid (PDA) when patients choose to exercise, for which 
the insulin pump bolus calculator does not provide insulin dosing or carbohydrate 
intake recommendations. If the BG at ti+1 was low or at target and the PDA 
suggested nothing or suggested consuming carbohydrates the recommendation from 
the PDA was considered appropriate; if the PDA recommended insulin, then the 
recommendation was deemed not appropriate. If the BG at ti+1 was high and the 
PDA suggested insulin the recommendation from the PDA was considered 
appropriate; if the PDA suggested no insulin or recommended consuming 
carbohydrates, then the recommendation was not considered appropriate. Given 
that the PDA is not compared against another calculator, outperformance is not 
defined. 
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6.4 Conclusion 
Here we have proposed novel methods for assessing the performance of insulin 
bolus calculators.  This method is low-cost and low-risk as it is designed to use data 
collected from prospective studies to retrospectively compare a proposed bolus calculator 
against a conventional approach for prandial insulin dosing (i.e. gold standard).  In the 
next chapter, we will apply these techniques to assess the performance of the iDECIDE 
algorithm, presented in Chapter 5, against the Medtronic MiniMed, Inc. insulin pump 
bolus calculator [28] (Aim 4).   
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7 RETROSPECTIVE ANALYSIS OF THE IDECIDE DECISION AID VS. 
CONVENTIONAL APPROACHES TO PRANDIAL INSULIN DOSING 
7.1 Introduction 
In Chapter 6 we proposed novel methods to retrospectively compare insulin bolus 
recommendations (Aim 4).  In this chapter, we apply the methods to: 1) test the 
performance of the iDECIDE decision aid, explained in Chapter 5, against the Medtronic 
MiniMed, Inc. [28] IPBC described in Chapter 2, and 2) evaluate the performance of 
iDECIDE’s recommendations in events when the patient exercises or drinks alcohol and 
no recommendations are provided by the Medtronic IPBC.  The results from applying the 
proposed methods will help to validate the hypothesis that postprandial blood glucose 
levels can be improved by providing insulin bolus (IB) or carbohydrate recommendations 
that account for meal and alcohol carbohydrates, exercise and glycemic excursions. 
In this study, 15 patients with T1D using insulin pumps were recruited.  
Informatics capabilities inherent in their insulin pump devices were used to gather 
glucose and insulin bolus data.  Self-reported data on alcohol and exercise, along with the 
pump data, were collected for 30 days, see Tables 7.1, 7.2 and 7.3 for the tabular format, 
respectively.  The methods described in Chapter 6 were used to compare the IPBC 
against iDECIDE, a decision aid that accounts for carbohydrates, alcohol and exercise to 
make recommendations. 
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Table 7.1: Sample of self-reported alcohol consumption in tabular format.  
Participants reported the time, drink type and volume.  Carbohydrates that were 
included in the insulin bolus calculation were also reported. 
Timestamp Drink Category Carbs Volume (mL) 
03/30/2016 08:26:00 PM Beer 5 237 
03/31/2016 07:50:00 PM Wine 0 100 
04/01/2016 09:00:00 PM Wine 0 148 
 
Table 7.2: Sample of self-reported exercise in tabular format.  Participants reported 
the start time, duration and intensity of the exercise. 
Timestamp Intensity Duration 
03/30/2016 06:58:00 AM Moderate 65 
03/31/2016 08:32:00 AM Light 255 
04/01/2016 07:30:00 AM Vigorous 50 
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Table 7.3: A sample of insulin pump data paired with a continuous glucose meter.  
Two instances of accessing the insulin pump bolus calculator are shown, and the 
carbohydrates consumed are included in these data. 
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When comparing iDECIDE against the IPBC, equivalent insulin 
recommendations were made in 63% cases and iDECIDE outperformed in 23% while the 
IPBC outperformed in 14%.  When comparing iDECIDE against participants’ self-
determined boluses (bolus amounts delivered by participants without consulting the IPBC 
or overriding recommendations form the IPBC), iDECIDE made equivalent 
recommendations in 36% of the events and outperformed in 37% and the participants 
outperformed in 27%.  iDECIDE made appropriate recommendations in 64% of the 
alcohol events and 75% of the exercise events. 
Preliminary results from this research were presented as posters at the Diabetes 
Science and Technology Meeting 2015 and the American Diabetes Association 76th 
Scientific Session 2016 [83,106] (APPENDIX A.4 and A.5).  An extended version of 
those posters has been published in the Journal of Diabetes Science and Technology 
[107] (APPENDIX C.3).  Chapter sections 7.2 through 7.4 comprise the portions of the 
published manuscript that deal with subject recruitment, data collection and results from 
applying the novel methodology.  The portions of the published manuscript, i.e. 
introduction of the novel methodology to compare insulin dosing algorithms, was 
presented in Chapter 6.  
7.2 Background 
Current standards of care for patients with type 1 diabetes (T1D) advocate for 
tight control of blood glucose (BG) [8]. One treatment challenge for patients with T1D is 
optimization of postprandial glucose levels [115–117]. To help patients achieve improved 
glucose regulation, continuous subcutaneous insulin infusion devices (CSII, aka “insulin 
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pumps”) sometimes coupled with continuous glucose monitoring systems (CGMs), have 
been developed. Although devices can assist patients in making insulin dosing decisions 
through the use of bolus calculators, it is unknown how accurate the bolus 
recommendations are in real-life scenarios when complex lifestyle choices, such as 
exercise and alcohol intake, have to be considered in decision making. Recent data 
suggests that patients are often confused and inconsistent when trying to factor in these 
behaviors when deciding insulin doses [73,93]. 
The aim was to apply the proposed method (Chapter 6) in a real-life setting to test 
the performance of the iDECIDE evidence-based IB algorithm against the bolus 
calculator of an insulin pump, and share lessons learned from collecting, aggregating and 
analyzing real-life data generated by insulin pumps and self-reported patient behaviors.  
7.3 Methods and Materials 
7.3.1 Description of the iDECIDE Evidence-based based Insulin Bolusing Dosing 
Decision Aid 
iDECIDE, the PDA evaluated here, is an evidence-based decision aid to 
recommend IB doses, carbohydrate intake, or both, by taking into account carbohydrates 
and alcohol consumed, and/or exercise plans [22]. The PDA was deployed as a 
smartphone app to help patients with T1D incorporate varied lifestyle choices 
simultaneously into decisions about prandial insulin dosing. The PDA is based on the 
formula proposed by Colin [29] to include alcohol [17,44], exercise [11,12,15,30] and the 
absorption rate of rapid-acting insulin [105], The PDA corrects to the nearest target 
glucose setting when the blood glucose is out of range,  but  would not account for the 
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CGMS trendline. Exercise is accounted for based on body weight and duration and 
intensity of exercise, while the alcoholic beverage type and volume consumed are 
necessary to adjust for alcoholic beverages.  
When the user launches the PDA application the first time he is prompted to set 
up a diabetes profile: weight, insulin-to-carbohydrate ratios, target BG levels, correction 
factors and active insulin time [118].  Although participants did not set up their user 
profile for the study, those that did not use paper logs interacted with the self-reporting 
module to log (1) exercise, describing duration and intensity, (2) food intake, specifying 
food type, serving size and carbohydrate content, and (3) alcohol intake, indicating 
number of drinks, size, and type of drink (Figure 7.4). In addition, when self-reporting 
plans, the user is expected to enter the BG reading. The PDA subsequently recommends 
an IB or carbohydrate intake by incorporating current evidence on the way food and 
alcohol carbohydrates and exercise influence BG, but these recommendations were 
assessed retrospectively and were not provided to the participants. 
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Figure 7.1: Screenshots of the iDECIDE mobile application: A) Self-reported 
exercise plans; B) Self-reported plans for food and alcohol consumption; C) 
Summary of relevant preprandial information; D) Advice to take 5 grams of snack 
carbohydrates to avoid exercise-induced hypoglycemia. 
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7.3.2 Participant Recruitment 
Following Institutional Review Board approval (APPENDIX E 
First round of recruitment of Mayo patients with Type 1 diabetes: Mayo Clinic 
IRB Approval #14-004649, APPENDIX F 
Second round of recruitment of Mayo patients with type 1 diabetes: Mayo Clinic 
IRB Approval #15-006155), 31 study participants were recruited from an outpatient 
academic endocrinology practice. Patients with T1D 18 years or older who had been 
under the care of the endocrinology team while on CSII therapy using a Medtronic 
MiniMed, Inc. (Minneapolis, MN) [28] insulin pump for at least one year were eligible to 
participate.  
7.3.3 Data Collection 
Participants were asked to continue their usual fitness and nutrition routine. For 
30 days, participants recorded their exercise activity and alcohol consumption via paper 
logs or the self-reporting module of the PDA, according to subject’s preferences. 
Exercise was recorded by start time, duration and intensity, and categorized as light, 
moderate or vigorous. Alcohol was recorded by tracking drink time, type, volume, and 
number (e.g. 6PM, 1 pint of beer, no carbohydrates entered).  Carbohydrate content was 
entered in the insulin pump.  After 30 days, logs were manually encoded into tables or 
downloaded from a secure cloud-based server. 
Self-reported data on exercise and alcohol was used as input for the PDA. For 
exercise, the PDA recommends an IB or carbohydrate intake by considering body weight 
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and intensity and duration of exercise [11,12,15,30]. For alcohol, the PDA accounts for 
the carbohydrates of the alcoholic drinks based on type, volume and count.  
CSII data from the corresponding 30-day timeframe was downloaded in tabular 
format. CSII device data included carbohydrates recorded by the participant, BG levels 
either from a continuous glucose monitoring system (CGMS) or capillary BG monitor or 
both, amount of insulin delivered, pump settings, and the IB suggested by the insulin 
pump bolus calculator (IPBC). 
7.3.4 Data analysis 
Computer programs were written to automate the process of collating and 
analyzing the data generated by the insulin pumps with the self-reported patient 
behaviors, see Figure 4.1. Assessing the performance of the PDA at ti+1 against the IPBC 
was automated as was the comparison of the PDA against participants’ self-dosing 
choices when the IPBC was not used as anticipated. The computer programs were able to 
identify and extract all of the information needed for the PDA to make a recommendation 
at time t, which included storing previously delivered boluses in memory in order to 
calculate IOB. The computer programs then scanned ahead in order to identify the 
postprandial glucose at time ti+1 and categorized the outcome according to participant 
glucose targets (below, at, or above target).  Example 1: depicted in Figure 7.1. B) is the 
consumption of a meal at 19:40 (time = t) of 50 grams of carbs accompanied by a blood 
glucose check.  The participant delivered the same amount of insulin as recommended by 
the pump.  The PDA would have used the information in that row to make an insulin 
bolus recommendation.  The outcome of the insulin pump recommendation was 
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identified at 22:40 (time = ti+1) where the CGMS recorded 161 mg/dL, which was 
considered above target due to the target blood glucose range of 85-120 mg/dL.  Example 
2: a meal containing 40 g of carbs was consumed at 20:45 which was also accompanied 
by a blood glucose check.  In this case the participant chose to override the 
recommendation made by the insulin pump bolus calculator.  The PDA would have made 
an insulin recommendation at this point, which included a calculation of IOB from the 
previous insulin bolus.  In this case the PDA would have been compared against the 
insulin delivered by the participant and not the recommendation from the insulin pump.  
If available, the computer program would have scanned ahead to obtain the postprandial 
glucose in order to determine which bolus amount outperformed.   
7.4 Results 
7.4.1 Participant characteristics and data 
There were 31 participants recruited for the study, with 4 withdrawals. Of the 
remaining 27 participants, a subset of 15 participants (Table 7.1) had pre-prandial glucose 
readings paired with ti+1 BG readings, with 13 of them on CGMS (9 on Minimed 530G-
551, 3 on Minimed 530G-751, and 1 on Paradigm Revel-723).  
A total of 2,104 events had postprandial glucose readings that allowed for a 
comparison between the IPBC and the PDA, and there were 419 events where the PDA 
was compared against cases where the participants did not use their IPBC, they overrode 
the IPBC recommendations, or they did not provide a prandial BG. There were 235 
exercise and 105 alcohol events that had sufficient data for analysis. Most (56%) exercise 
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events were of moderate intensity. There were few (14%) alcohol events where 
participants accounted for the carbohydrates associated with the beverage.   
IPBCs allow different settings (BG target, insulin-to-carbohydrate ratio, and 
correction factor) throughout the day and the PDA accounted for these different settings 
for each participant at each time of day.  While participants used different Medtronic 
insulin pumps, all use the same formula for computing IB recommendations, and an 
adaptation of [119] for computing active insulin. The Medtronic 530G includes a 
threshold suspend feature, that is designed to automatically stop insulin delivery when the 
CGMS value falls below a patient-specific pre-set threshold.  There were 5 insulin 
suspension events that occurred in close temporal proximity to events of interest; such 
low frequency did not warrant removing data from the analysis. 
Table 7.4: Demographics of 15 subjects with Type 1 diabetes.  Data reported as 
mean (SD) or %. 
Characteristic Value 
Age (years) 48.7 (13.9) 
% Women 73.3 
% White 93.3 
Hemoglobin A1C 7.5 (1.2) 
Diabetes duration (years) 26.9 (11.8) 
Duration on insulin pump (years) 11.5 (5.3) 
Daytime Low/High Target BG 89.9 (8.6) / 112.3 (10.8) 
# Analyzable exercise events/day 1.1 (0.34) 
# Analyzable alcohol events/day 0.2 (0.18) 
 
  
92 
 
7.4.2 Comparison of iDECIDE against the insulin pump bolus calculator or participant 
We used the algorithm described in Figure 6.1 to compare the appropriateness of 
the PDA’s recommendations against events when the patient followed the IPBC 
recommendations for BG correction doses and/or carbohydrate loads that included a 
prandial and postprandial BG.   
The first assessment was was how the PDA (i.e. iDECIDE) compared against the 
IPBC (Table 7.2).  The IPBC brought the participants to target glucose levels in 13% 
(278/2104) events, below target in 10% (207/2104) and above target in 77% (1619/2104). 
When considering very low and very high postprandial BG, the BG was below 70 mg/dl 
in 3% (55/2104) and over 180 mg/dl in 35% (737/2104).  When considering instances 
where glucose was below target, iDECIDE would have recommended an appropriately 
smaller dose in 14% (28/207), but a larger dose in 13% (27/207) and an equivalent IB in 
73% (152/207). For glucose levels at target, iDECIDE would have suggested an 
equivalent IB in 58% (162/278) compared to the subject’s IPBC, but a higher dose in 
20% (56/278) and lower in 22% (60/278). In events where post-prandial glucose was 
higher than target, iDECIDE would have suggested a higher dose in 25% (406/1619), a 
lower dose in 13% (212/1619), and an equivalent dose in 62% (1001/1619). Overall, 
iDECIDE would have recommended an equivalent dose compared to the IPBC in 63% 
(1315/2104) of IB decisions. 
We used the algorithm in Figure 6.1 to compare the appropriateness of the PDA 
against decisions made by the participant (Table 7.2).  The participants self-dosing led to 
above target postprandial glucose in 76% (319/419), below target in 13% (54/419) while 
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participants only achieved target glucose levels in 11% (46/419).  There were 3% 
(14/419) of the events with a postprandial BG below 70 mg/dl and 37% (154/419) over 
180 mg/dl. When considering instances where glucose was below target, iDECIDE 
would have recommended an appropriately smaller dose in 43% (23/54), a larger dose in 
19% (10/54), and an equivalent IB dose in 38% (21/54). For glucose levels at target, 
iDECIDE would have suggested an equivalent IB amount in 9% (4/46) compared to the 
subject’s own decision, but a higher dose 39% (18/46) and lower in 52% (24/46). In 
situations where post-prandial glucose was greater than target, iDECIDE would have 
suggested a higher dose in 34% (107/319), a lower dose in 27% (86/319), and an 
equivalent dose in 39% (126/319). Overall, iDECIDE would have recommended an 
equivalent IB in only 36% (151/419) of instances compared to when the participant made 
their own decisions. 
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Table 7.5: Results from retrospective comparison of the appropriateness of the 
recommendations from iDECIDE's algorithm against the insulin pump bolus 
calculator (IPBC), and from iDECIDE's algorithm against the participant's self-
dosing choices.1 
Event type 
Postprandial BG 
(mg/dl) 
iDECIDE insulin recommendations 
Total 
Larger 
Dose 
Smaller  
Dose 
Equivalent 
Dose 
IPBC 
 
Low  
(< target) 
27 ‡ 28 † 152 § 207 
Target  
(participant target) 
56 ‡ 60 † 162 ¶ 278 
High  
(> target) 
406 † 212 ‡ 1,001 § 1,619 
TOTAL 489 300 1,315 2,104 
Participant 
Low  
(< target) 
10 ‡ 23 † 21 § 54 
Target  
(participant target) 
18 ‡ 24 † 4 ¶ 46 
High  
(> target) 
107 † 86 ‡ 126 § 319 
TOTAL 135 133 151 419 
 
                                                 
1 † iDECIDE recommendation was appropriate and insulin pump bolus calculator (IPBC) 
(or participant) was not appropriate, iDECIDE outperformed the bolus calculator (or 
patient). When iDECIDE recommends a lower insulin dose recommendation than the 
bolus calculator (or participant) and the postprandial BG is on target, iDECIDE could 
potentially avoid a hypoglycemic event and therefore outperformed the bolus calculator 
(or participant).   
‡ Bolus calculator (or participant) was appropriate and iDECIDE recommendation was 
not appropriate, Bolus calculator (or participant) outperformed iDECIDE.  
§ Events where iDECIDE and bolus calculator (or participant) recommendations were 
not appropriate. 
¶ Events where iDECIDE and bolus calculator (or participant) recommendations were 
appropriate. 
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7.4.3 Assessment of the appropriateness of iDECIDE’s recommendations for exercise 
and alcohol 
In cases of exercise and alcohol the pump does not suggest insulin. In these cases, 
the PDA is only assessed based on the BG outcomes since it could not be compared 
against the IPBC. We used the algorithm described in Figure 6.2 to assess the 
appropriateness the PDA’s recommendations when alcohol consumption was recorded.  
As reported earlier, patients self-reported accounting for the carbohydrate content of the 
beverage in 15 of the 105 events. As indicated in Table 7.3, in 64% (67/105) of overall 
alcohol events the PDA would have provided appropriate advice.  The PDA performed 
well when the postprandial BG was high with 78% (64/82) appropriate IB 
recommendations, but had poor performance when the postprandial BG was at target 
with only 5% (1/19) recommendations deemed appropriate. 
Table 7.6: Results from assessing the appropriateness of the recommendations 
regarding insulin dosing for alcohol consumption from the iDECIDE algorithm. 
Postprandial BG 
iDECIDE recommendations 
Total 
Appropriate Not Appropriate 
Low (< target) 2 2 4 
Target (participant target) 1 18 19 
High (> target) 64 18 82 
TOTAL 67 38 105 
  
We used the algorithm described in Figure 6.3 to assess the appropriateness of the 
PDA’s recommendation before exercise (Table 7.7: Results from assessing the 
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appropriateness of the recommendations regarding insulin dosing and carbohydrate 
ingestion for exercise from the iDECIDE algorithm.4).  The PDA appropriately 
suggested insulin or to ingest carbohydrates in 75% (176/235).  Similar to the alcohol 
results, the PDA performed well when post exercise BG was high 87% (154/178), but 
only made appropriate suggestions in 37% (10/27) and 40% (12/30) when the post 
exercise BG was low or target, respectively.  There were 26 exercise events that had a 
duration of 90 minutes or longer and the PDA made appropriate recommendation in only 
27%. 
Table 7.7: Results from assessing the appropriateness of the recommendations 
regarding insulin dosing and carbohydrate ingestion for exercise from the iDECIDE 
algorithm. 
Post exercise BG 
iDECIDE insulin dose 
and carbohydrate recommendations 
Total 
Appropriate Not Appropriate 
Low (< target) 10 17 27 
Target (participant target) 12 18 30 
High (> target) 154 24 178 
TOTAL 176 59 235 
 
7.5 Discussion 
Although advances in in-silico model technology have allowed for incorporation 
of new features into existing technologies to improve BG control, these often do not 
account for variables that affect BG (e.g. exercise, stress, sleep and illness).  Decision 
aids that assist patients with T1D to make better prandial insulin dosing decisions are 
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needed, particularly when patients must account for multiple simultaneous lifestyle 
variables that may impact BG levels.  
One of the main differences between this study and others that retrospectively 
evaluated the performance of prandial insulin dosing algorithms is the source of the 
clinical data. For instance, previous studies have compared the effectiveness of insulin 
dosing algorithms in controlled environments such as in the ICU [114,120], where 
glucose control is closely monitored and tracked and lifestyle behaviors are not a factor. 
In contrast, this study focused on free-living outpatients who made their own choices 
about insulin therapy, and where individual lifestyle choices have the potential to impact 
treatment decisions and outcomes.  
One of the analytic challenges we encountered when developing, testing, and 
comparing the effectiveness of insulin dosing algorithms is the complex nature of data 
generated from free-living participants. In our study, many of the self-management and 
daily living activities recorded by the participants occurred in tight temporal succession 
and could not be assessed as isolated events. This required development of a new analytic 
approach to evaluating the data. An unexpected positive outcome of this study was 
gaining a better understanding of patients’ self-management behaviors as they interact 
with insulin pumps [73,93].  
The methodology outlined here permitted an assessment of how our PDA would 
perform when used in different scenarios. When compared to the IPBC embedded in the 
subject’s insulin pump, iDECIDE in general was non-inferior, recommending IB doses 
equivalent to the IPBC standard in 63% of decisions overall and nearly equivalent 
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number of smaller doses when glucose levels were below or at target. There were some 
instances, 23% (494/2104), where iDECIDE was superior to the IPBC, such as when it 
would have recommended larger doses in cases when glucose levels were above target.  
Initial analysis of iDECIDE in cases where the doses were too large or small, provided 
insights which were used to improve performance with continuing analysis necessary for 
further refinement of the recommendations [83,106].  For instance, we used an initial 
setting of 3 hours of active insulin time to calculate IOB.  To improve performance, this 
was later adjusted to 4 hours which reduced the number of inappropriate 
recommendations that could have led to hypoglycemia.  In the future, iDECIDE should 
be adapted to the insulin action time specified for each patient.  
Employing the analytic paradigms developed here, we also assessed the 
performance of iDECIDE when there was a lack of recommendations from the IPBC 
with exercise and alcohol events.  In these analyses the postprandial glucose was used as 
the outcome measure.  For cases involving alcohol consumption, iDECIDE may have 
offered an advantage with deciding a compensatory insulin bolus. iDECIDE could have 
improved post-exercise BG when the duration was 90 minutes or less and the iDECIDE 
should be restricted to such events until further study.  
There are limitations to the study. This study incorporated self-reported data for 
exercise, meal and alcohol behaviors. It is possible participants did not record all these 
events, or may have recorded them inaccurately. Also, participants’ insulin pump settings 
were not adjusted for the study.  Inappropriate insulin pump settings, such as basal rates, 
could have influenced the results.  Sample sizes for alcohol and exercise events were 
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small with respect to the larger comparisons involving the IPBC. The study also did not 
consider late-onset hypoglycemia that can arise from engaging in exercise, and possibly 
when consuming alcohol.  To automate the analysis, we opted against determining an 
appropriate post-exercise timeframe on a case by case basis and instead focused on the 
immediate effects of exercise by employing a standard 15-minute post-exercise time-
frame.  Considering BG levels outside of the time-frames used for analysis in this study is 
another important factor to consider in the future when assessing and calibrating IB 
calculators. 
In addition, the analysis was done retrospectively. A prospective analysis, where 
iDECIDE makes suggestions in real time, would help further delineate its capabilities, 
improve performance and assess user acceptance. A recent analysis suggests that mobile 
apps can offer advantages in diabetes management, but more rigorous studies are needed 
[121]. Finally, the analytic algorithms tested here were for a very specialized group of 
patients (T1D on insulin pumps) and we did not conduct an analysis of the outcomes in 
relation to A1c scores. Testing these methodologies in a wider selection and more diverse 
population of patients (e.g. T1D patients on multiple daily insulin injections or patients 
with type 2 diabetes) would be needed to test the generalizability of the approach. 
7.6 Conclusion 
We introduced an analytic method to use prospective real-life data to 
retrospectively compare insulin dosing recommendations (Chapter 6).  This novel 
methodology was used to assess the recommendations of iDECIDE, an evidence-based 
decision aid (Aim 4).  The analysis done with the novel methods validates the hypothesis 
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that postprandial glucose levels of adult patients with T1D can be improved by providing 
insulin bolus or carbohydrate recommendations that account for meal’s carbohydrates, 
glycemic excursion, alcohol consumption and planned exercise.  The results presented in 
this study support the case for accounting for planned exercise, while accounting for 
carbohydrates from alcohol is not definitive at this point. 
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8 DESIGN AND DEPLOYMENT OF THE IDECIDE DECISION AID AS A 
SMARTPHONE APPLICATION 
8.1 Introduction 
Exercise and alcohol have an effect on blood glucose, but as discussed in Chapter 
2, there are currently no decision aids that account for those two variables when 
suggesting insulin boluses (Aim 1), despite patients’ daily needs for adjusting for 
exercise and alcohol to improve glycemic control (Chapters 3 and 4) (Aim 2). Results 
from a completed retrospective analysis performed using proposed novel methodological 
approaches demonstrated that the iDECIDE insulin dosing algorithm could lead to 
improved glycemic control when compared against a proprietary insulin pump bolus 
calculator (Chapters 6 and 7) (Aim 4). 
In this chapter, we discuss completed and future work to deploy the proposed 
iDECIDE insulin dosing algorithm as an iOS smartphone application (app) (Aim 5).  
8.2 Background 
Mobile technology, such as smartphone apps, show promising results in their 
ability to improve health outcomes due to their low-cost and high penetration of 
smartphone ownership [122].  But researchers have yet to confirm the effectiveness of 
app-based interventions in improving glycemic control in patients with T1D, which is 
likely due to the lack of high quality controlled trials [121,123].   
Although there are over 1,000 diabetes apps available for download, unfortunately 
very few undergo usability testing and most are not evidence-based [124,125].  Currently, 
clinicians and patients rely on app ratings and reviews from other users when selecting a 
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diabetes app.  While good ratings may be indicative of the usability of the app, it is not 
possible to translate app ratings into improved health outcomes for the users [60]. 
In a systematic review of diabetes mobile apps, researchers found that a large 
number of the apps were merely digital versions of logbooks and many only provided one 
functionality out of many of the desirable tasks for self-management that are feasible to 
be implemented with mobile technology [126].  Other limitations of the reviewed apps 
were data entry issues and integration with electronic health records.  Another systematic 
review of diabetes apps found that the majority of the apps were similar to each other and 
that they typically only offered one or two functions [60].  The authors from this review 
indicated that providing multiple functionalities would be beneficial to producing an app 
for diabetes self-management and that patients and clinicians should be part of the app 
development process.   
According to Goyal, et.al. [127], diabetes apps should provide the following 
functionalities: monitor BG and objectively track medications, nutrition, exercise and 
body weight.  A recent study was only able to identify 9 apps out of 965 that were free 
and available for download from Apple [128], Google (Android) [129], or Microsoft 
(Windows) [130] app stores that provided the four functionalities [131].  These results 
indicate that there is a gap between evidence-based research and the apps available in the 
marketplace. 
There are very few apps that provide decisional support, for example, providing 
recommendations for bolus insulin.  Two such apps are “Diabeo” [132] and “”ABC4D” 
[133–135].  Diabeo uses carbohydrate loads, blood glucose and planned exercise to make 
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insulin recommendations.  Additionally, Diabeo uses an algorithm to automatically adjust 
ICR and basal rates when postprandial glucose levels do not fall within a predetermined 
target range.  A 6-month clinical trial demonstrated the app’s ability to improve HbA1c 
scores in patients with T1D [132].  The ABC4D app uses case-based reasoning to make 
insulin recommendations for meals.  Meal instances and glycemic outcomes for an 
individual are described by a set of 10 parameters which are stored and later referenced 
by ABC4D in order to make insulin recommendations by matching the current meal to a 
similar one stored in memory.  A 6-week study showed that out of the 10 possible 
parameters for the bolus calculator, participants used exercise and alcohol the most [135].  
The safety, but not efficacy, of the app was demonstrated by a decrease in the number of 
hypoglycemic events during the study period [134].   
Although there are similarities between the bolus calculator capabilities of 
Diabeo, ABC4D and iDECIDE, iDECIDE is different in that it not only makes insulin 
recommendations, but also recommends carbohydrates.  The recommendations from 
iDECIDE are transparent and can be broken down and understood by patients and 
clinicians.  Insulin recommendations from Diabeo and ABC4D use artificial intelligence 
methods when making insulin recommendations, which can make it difficult for patients 
and clinicians interpret the reasoning behind the recommendations.  Also, the iDECIDE 
app includes other functionalities beyond providing insulin and carbohydrate 
recommendations.  iDECIDE provides several features for self-tracking meals and 
assistance with carbohydrate counting, such as suggested carbohydrate content of 
alcoholic beverages, barcode and text search access to food databases, a user-specified 
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favorite foods list, and documenting meals with a photograph.  iDECIDE also provides 
links to educational material, allows users to set their iDECIDE calculation parameters 
(e.g. ICR, CF and target BG), and integrates with Apple’s HealthKit [136].  These 
functionalities are presented in more detail in this chapter.  
The objective was to design and deploy the iDECIDE decision aid as an app that 
incorporates the evidence-based bolusing algorithm in order to improve glucose control. 
8.3 Methods and Materials 
Prototypes of the iDECIDE app were developed with Proto.io [137], Justinmind 
[138], Android Studio [139] and PhoneGap [140].  For the development of the iDECIDE 
app as a clinical decision support system (CDSS) we adopted the conceptual model 
proposed by Greenes in [141], where the iDECIDE app is composed of a knowledge 
base, an information model, an execution engine and results (output generation) (Figure 
8.1). As suggested by Greenes, the modular deployment of the iDECIDE application has 
the potential to facilitate future updates and maintenance of the CDSS. In the next 
subsections, we explain the iDECIDE’s implementation modules in more details. 
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Figure 8.1: The user of the iDECIDE app input information about his endocrine 
settings and plans for meals, alcohol and/or exercise which are saved to the 
knowledge base through the results module.  The information model specifies the 
data format for the knowledge base.  The execution engine reasons over the data 
stored in the knowledge base to make recommendations for insulin and/or 
carbohydrates to maintain glycemic control.  The recommendations are output to 
the user on a smartphone via the results module. 
 
8.3.1 User 
The intended users of the iDECIDE app are adults with type 1 diabetes who self-
manage glycemic control with intensive insulin therapy which can be delivered via one of 
two treatment options: multiple daily injections (MDI) or continuous subcutaneous 
insulin injections (CSII).    The user interacts with iDECIDE by self-reporting endocrine 
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settings and lifestyle preferences that have an effect on blood glucose levels.  The user 
then receives recommendations from iDECIDE to maintain glycemic control.  
8.3.2 Information Model 
iDECIDE’s information model was specified as a Unified Modeling Language 
(UML) class model, see Figure 8.2.  The information model supports the three functions 
of iDECIDE:  
1. store user endocrine settings, 
2. track daily meals, alcohol and planned exercise, 
3. apply the evidence-based iDECIDE algorithm to recommend pre-meal 
bolus and/or carbohydrate intake based on current blood glucose, alcohol 
and food intake, exercise plans and endocrine settings. 
8.3.2.1 Setup user’s endocrine settings 
Upon launching the iDECIDE app for the first time the Diabetes Patients is 
prompted to self-report their diabetes profile settings: Target Glucose, correction factor 
(CF), insulin to carbohydrate ratio (ICR) and body weight.  Target Glucose, CF and ICR 
are Endocrine Test Findings; the values for these settings are advised and guided by the 
patient’s endocrinologist.  For example, ICR could be set to 10 mg/dL for the a full 24-
hours, see Figure 8.3.  iDECIDE supports the storage of multiple values for each of the 
three endocrine settings over a 24-hour period, for example, ICR could be set at 10 
mg/dL from midnight to 4:00 p.m. and a value of 15 mg/dL could cover the remainder of 
the day from 4:00 p.m. to midnight.  Target Glucose, CR and ICR, along with weight, are 
Observable Entities that belong to the Diabetes Patient. 
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8.3.2.2 Self-tracking meals, alcohol, and exercise 
iDECIDE can be used to record Plans made related to carbohydrates from meals 
(Carbs Plan), alcoholic intake (Alcohol Plan), exercise (Exercise Plan) and delivered 
insulin (Insulin Plan).  Alcohol Plans also have Carbs Plans based on the type and 
amount of alcohol consumed.  An example of a combination of a Carbs Plan along with 
an Alcohol Plan could be to consume 2 slices of pizza that contains 35 grams of carbs 
(Figure 8.3.B) while also having a 12-ounce beer that consists of 8 grams of carbs (Figure 
8.3.C).  A potential Exercise Plan could be to engage in 30 minutes of light activity at 
noon (Figure 8.3.E).  An example of a more complex Exercise Plan would be to warm up 
with 10 minutes of moderate activity at 7:00 a.m., followed by 20 minutes of intense 
activity at 7:10 a.m.  An example of an Insulin Plan is to bolus 3 units of insulin at 6:30 
p.m. 
8.3.2.3 Apply evidence-based algorithm 
iDECIDE uses an Evidence-based algorithm to generate insulin bolus (Insulin 
Plan) or carbohydrate intake (Carbs Plan) Recommendations based on endocrine settings 
(Observable Entities) and Plans for carbohydrates (Carbs Plan), alcohol (Alcohol Plan) 
and exercise (Exercise Plan).  The dosing algorithm also considers previous Insulin Plans 
that the user delivered (commits) in order to determine how much insulin is on board 
(IOB Evidence) (Table 5.1).  While the user is self-tracking carbohydrates, alcohol and 
exercise, they are also prompted to provide a current blood glucose reading (Current 
BG).  In the case when the meal that consisted of 2 slices of pizza (Carbs Plan) and a 
beer (Alcohol Plan) the current blood glucose (Current BG) was 135 mg/dL, iDECIDE 
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recommends the diabetes patient to deliver 4.8 units of insulin (Insulin Plan) (Figure 
8.3.D).  In the exercise example (Exercise Plan) of 30 minutes of light activity at noon 
with a current blood glucose of 107 mg/dL, iDECIDE recommends the diabetes patient 
consume a snack of 5 grams of carbohydrates (Carbs Plan) (Figure8.3.F). 
 
Figure 8.2: UML class diagram depicting the information model of the iDECIDE 
app.  The classes and relationships support the three functionalities of the app: 1) 
store endocrine settings; 2) self-track meals, alcohol and exercise; 3) apply relevant 
evidence to recommend insulin bolus or carbohydrates based on current blood 
glucose, carbohydrates, alcohol, planned exercise and endocrine settings. 
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Figure 8.3: Screenshots of the iDECIDE app; A) setting the endocrine setting: 
insulin to carbohydrate ratio (ICR); B) self-tracking a meal with carbohydrates; C) 
self-tracking an alcoholic beverage; D) iDECIDE’s insulin recommendation to cover 
carbs associated with a meal, alcohol and out-of-range blood glucose; E) self-
tracking exercise; F) iDECIDE’s carbohydrate recommendation to compensate for 
exercise. 
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The Alcohol Evidence breaks alcoholic beverages into five classes based on the 
carbohydrate and alcohol content of one standard serving size (Figure 5.2), which values 
are used to adjust the amount of insulin recommended.  Exercise Evidence has two 
components: reduce the insulin bolus and/or suggest taking a carbohydrate snack.  The 
reduction of insulin considers the duration and intensity of the exercise (Table 5.2) while 
suggesting carbohydrates takes into account body weight and exercise duration (Tables 
5.3 and 5.4).  A complete description of the evidence-based insulin dosing equation is 
found in Chapter 5. 
8.3.3 Knowledge Base 
As discussed in Chapter 5, relevant evidence is incorporated into the insulin 
dosing algorithm in order to provide recommendations for insulin or carbohydrates.  The 
static portion of the knowledge base includes: user’s self-reported endocrine settings 
(Target Glucose, CF, ICR), the categorizing of alcoholic beverages and the effect on 
glycemic control (Alcohol), the effects of exercise on blood glucose (Exercise), as well as 
the evidence for calculating IOB.  Dynamic portions on the knowledge base incorporate 
real-time data entry when the user engages in self-tracking of meals (Carbs Plan), 
alcohol (Alcohol Plan), exercise (Exercise Plan) and current blood glucose (Current BG). 
8.3.4 Execution Engine 
The execution engine is comprised of the proposed evidence-based insulin 
bolusing algorithm (Chapter 5).  The engine has access to the evidence (Alcohol, 
Exercise, IOB) which is encoded in a static format to the knowledge base.  The execution 
engine also accesses additional information that is user-generated which also populates 
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the knowledge base (Findings).   Real-time user input regarding current plans (Carbs, 
Alcohol and/or Exercise Plans) and the CurrentBG are required for the insulin bolus 
decision aid to make recommendations.  In short, the engine reasons over the patient’s 
stored endocrine settings and the current Plans to make suggestions for an Insulin Plan 
and/or a Carbs Plan while incorporating the appropriate Evidence based on the context of 
the situation. 
8.3.5 Input, Output and Results 
The results are related to how the CDSS presents output and elicits input from the 
user.  Interfaces have been designed that support the functionalities of iDECIDE, see 
Figure 8.3.  The interfaces and functionalities have been improved after two rounds of 
usability testing. 
8.4 Results 
In this section, we describe two usability studies of the iDECIDE app.  The 
author, Danielle Groat, conducted the first usability study under the direction of Dr. 
David Kaufman and Dr. Vimla Patel while enrolled in the course “BMI 591: Human 
Computer Interactions and Human Factors in Biomedicine.”  The second usability was 
carried out by Hiral Soni, a graduate student in the Department of Biomedical 
Informatics.  The first usability study served as a template for the follow-up study by 
influencing the content and flow of the tasks and questionnaires.  
8.4.1 Usability Testing, First Round 
For the first usability test we secured approval from the Arizona State University 
(ASU) IRB to recruit five Arizona State University (ASU) students, faculty or staff aged 
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at least 18 years. The iDECIDE app was installed as a native app to a ZTE N9130 
smartphone running the Android operating system (OS) 4.4.4 Kit Kat.  Participants were 
given a brief introduction to diabetes with a fictitious diabetes patient profile.  The 
Android smartphone with the iDECIDE app launched was then presented to the 
participant.  Participants were then given brief instructions to help them navigate the 
Android phone and then they were given instructions to think aloud as they interacted 
with the app.  Participants were given 5-minutes to explore the app and then a total of 7 
tasks were given one at a time.  The usability testing was recorded using Morae® [142] 
and real-time screenshots of the smartphone screen were simultaneously captured using 
Droid@Screen [143].  Upon completion of the tasks the participants were then given a 
usability survey which was a modified version of the System Usability Scale (SUS) as it 
was published by the Healthcare Information and Management Systems Society (HIMSS) 
[144].  The audio-video recordings were analyzed and annotated with Morae software.  
Participant errors and comments were noted and grouped into themes.  Time to complete 
tasks were measured.  
Five graduate students from ASU were recruited.  Three were female, two were 
male.  The average years of experience using a smartphone was 5.5 years. 
Table 8.1 shows the results of the average time it took to complete the tasks and 
the average number of errors associated with each task.  The exploratory task yielded the 
highest amount of errors while tasks 6 and 7 resulted in no errors from the participants.  
This suggests that users were able to learn the system over time. The average subjective 
usability rating from the System Usability Scale (SUS) questionnaire was 76.4, higher 
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than the average score of 68 for the SUS [145].  As the audio-video recordings were 
analyzed there were 7 usability issues, or themes, that emerged.   
Table 8.2 provides a brief description of each issue, the frequency of the issue 
across all the participants and the number of participants that were affected by the issue.  
The cursor issue with numeric data entry (Issue #2) had the highest number of errors.  
This was due to bug in the prototype that defaulted the cursor position to the right side of 
numeric data entry fields instead of the left side. 
Table 8.1: Quantitative results of usability evaluations.  All values are reported as 
means and standard deviation (SD). 
Task Time in minutes (SD) Number of Errors (SD) 
Exploratory 5.87 (1.80) 5.8 (4.32) 
1 0.71 (0.30) 1.0 (1.00) 
2 1.28 (0.46) 1.8 (0.84) 
3 1.95 (0.74) 2.0 (0.71) 
4 2.24 (0.76) 3.4 (1.52) 
5 0.95 (0.18) 0.2 (0.45) 
6 0.96 (0.58) 0.0 (0.00) 
7 1.20 (0.50) 0.0 (0.00) 
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Table 8.2: Usability issues and their frequency. 
#. Brief Description Frequency # Participants Affected 
1. Screen contents overwhelming 3 2 
2. Numeric data entry, cursor position 33 5 
3. Error in icon selection 12 5 
4. Unwanted functionality 7 3 
5. Desired functionality missing 7 3 
6. Slider obstructs visibility  1 1 
7. Scroll gesture interferes with time picker 2 2 
Total 65 5 
 
8.4.2 Usability Testing, Second Round 
For the second round of usability testing, received IRB approval from the Mayo 
Clinic (APPENDIX F 
Second round of recruitment of Mayo patients with type 1 diabetes: Mayo Clinic 
IRB Approval #15-006155). We recruited Mayo Clinic patients with type 1 diabetes. A 
prototype version of the iDECIDE app was built using Justinmind [138].  The usability 
study with the first participant was done by launching the iDECIDE prototype on an 
Android smartphone.  Unfortunately, this environment produced a considerable amount 
of lag and all subsequent studies with the remaining 5 participants were conducted with 
simulated smartphone screens on a laptop computer.  All the participants completed a 
total of 8 tasks, which included 5 minutes of exploration, 6 tasks specific to a fictitious 
diabetic character and 1 task to set up a personal fitness goal. The tasks included: setting 
the user’s profile, including endocrine settings, and setting up meal/alcohol/exercise plans 
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and goals. Morae® software was used to record interactive behaviors and their voiced 
thoughts during the testing.  
Table 8.3 shows the results of the average time it took to complete the tasks and 
the average number of errors associated with each task.  The number of errors remained 
fairly low across all the tasks with most problems occurring during first four tasks and 
patients gradually adapting to the app after 5 minutes of exploration. This may indicate 
that overall the app was easy to learn. 
A total of 13 issues were detected, see Table 8.4 for a brief description and 
frequency of errors.  Four of the issues did not require immediate changes. We made 
necessary changes to address the 9 remaining issues. For example, users found some 
icons confusing, therefore, we proposed new icons for carbohydrates, insulin to carb 
ratio, and insulin sensitivity. Most importantly, participants were unclear about 
differences between goals and plans, hence we replaced the notion of plans for logs.  The 
average SUS rating was 79.9, an above average SUS rating.  The interfaces depicted in 
Figure 8.3 were modified based on the results of the two usability tests. 
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Table 8.3: Quantitative results of usability evaluations.  All values are reported as 
means and standard deviation (SD). 
Task Time in minutes (SD) Number of Errors (SD) 
1 1.17 (0.58) 0.0 (0.0) 
2 4.67 (1.34) 2.0 (1.4) 
3 1.34 (0.58) 0.8 (0.4) 
4 0.36 (0.10) 0.0 (0.0) 
5 1.35 (0.74) 0.3 (0.5) 
6 2.56 (0.53) 1.3 (0.5) 
7 1.05 (0.65) 0.5 (0.5) 
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Table 8.4: Usability issues and their frequency. 
#. Brief Description 
Frequency 
during 
Exploratory task 
Frequency 
during 
Tasks 1-7 
# 
Participants 
Affected 
1. Confusion with the “+” button 1 1 1 
2. Confusion with endocrine 
settings 
3 2 3 
3. Repeat button selection 0 5 5 
4. Confusion with adding drinks 0 1 1 
5. Time slider 1 3 3 
6. Skipped task  0 4 3 
7. Felt lack of direction form app 0 1 1 
8. Confusion between goals and 
plans 
0 3 3 
9. Carbs icon meaning unclear 2 0 2 
10. Screen content overwhelming 1 2 3 
11. Lack of “no” for an option 1 0 1 
12. iDECIDE bottom bar  0 1 1 
13. Confusion with plans icons 0 1 1 
Total 9 24 6 
 
8.4.3 iDECIDE decision aid deployed for the Apple iOS iPhone 
At the conclusion of the 30-day study from the second calibration of the 
iDECIDE app (APPENDIX F: Mayo Clinic IRB #15-006155), participants were given a 
usability survey on the self-reporting module of the iDECIDE app (APPENDIX F.3).  
Nine of the participants responded to the web-based usability survey.  A Likert rating 
score from 1 to 5 was used to rate various aspects of the app with 5 being a positive 
rating.  The average rating across all questions was 3.8.  In the comments area, most of 
the responses were positive with some mention as to the areas that needed improvement.  
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The main themes that resulted from the comments was that participants desired more 
functionalities for logging meals and exercise and more flexible searching abilities for 
accessing food content. 
Here we present the interfaces and functionalities that were built for the Apple 
iOS version of the iDECIDE decision aid (Figure 8.4).  Most notably different is the 
color palate has been changed from a dark theme to a light theme.  Also, some of the 
widgets have been modified to align with the Apple’s developer’s guidelines and the built 
with the iOS platform interface kit.  As you can see in Figures 8.4.A and 8.4.B, there are 
additional functionalities for tracking meals and carbohydrates.  Using the Nutritionix 
food database [146], users can search for grocery foods with a barcode scanner while 
restaurant menu items and common foods are identified with a text search.  Nutritionix 
also provides access to the United States Department of Agriculture food composition 
databases [147].  The nutritional content of over 570,00 grocery items, 116,00 restaurant 
items and 24,700 common foods has been verified before their addition to the Nutritionix 
database.   
Additionally, users can now store a list of favorite food items that can be easily 
retrieved when reporting food intake to auto populate meal entry.  Photos of the meal can 
also be recorded with the food data entry (Figure 8.4.C).  In addition to providing an 
insulin (or snack in the case of exercise) recommendation, the user can also report any 
overrides made to the recommendation (Figure 8.4.D).  The interfaces for tracking 
exercise are relatively unchanged, Figures 8.4.E and 8.4.F.  The entry of endocrine 
settings has changed to allow up to three values over a 24-hour period, Figure 8.4.G.  
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HealthKit has been integrated into the app to allow read and write capabilities for blood 
glucose, carbohydrates, and body weight, Figure 8.4.H. 
 
Figure 8.4: iDECIDE interfaces for the iOS platform: logging meal with A) pizza, B) 
light beer, C) blood glucose and photo, D) insulin recommendation for meal, E) 
logging exercise, F) carbohydrate recommendation for exercise, G) setting insulin to 
carbohydrate ratio values for 24-hours, H) enabling read and write functionalities 
with HealthKit. 
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8.5 Discussion 
As mentioned earlier, the previous versions of the app were built with various 
prototyping software with the Android platform in mind.  The self-tracking module used 
by study participants was built as a multi-platform app with PhoneGap, again with the 
Android design guide contributing to the look and feel of the interfaces.  The final 
installment of iDECIDE is deployed on Apple’s iOS platform.  Apple has been chosen as 
the target platform for two main reasons.  According to the latest document from the 
FDA concerning mobile medical applications [148], iDECIDE falls under the regulatory 
requirements as a Class II medical device.  Although mobile medical applications can be 
deployed on any number of operating systems, currently the majority of applications that 
have been approved by the FDA have been for the iOS platform [149,150].  Most 
importantly, the demographics of diabetes patients at the Mayo clinic suggest that a 
greater number of them use Apple iPhones as opposed to other smartphones available on 
the market.  This is an important consideration as future research with the iDECIDE app 
will likely be conducted in collaboration with the Mayo Clinic and its patient population. 
One of the frameworks that has recently been released by Apple for iOS is 
HealthKit [136].  Mayo Clinic, HealthKit and Epic [151], an electronic health record 
vendor, have partnered to improve the ability of patients to share their health-related data 
with their providers via the MyChart patient portal from Epic.  At this point in time Mayo 
Clinic is preparing to transition to the Epic EHR, and when the transition is complete, the 
framework for patients to share data with providers in a timely fashion will be in place.  
Other health care institutions that are already using Epic have proven the feasibility of 
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patients with T1D using the Dexcom G5 Mobile CGMS with an insulin pump and the 
Dexcom iPhone companion app to be apple to wirelessly transfer their data in nearly real-
time to their providers through the Epic and MyChart platform interfacing with Apple’s 
HealthKit [152,153] 
In order for iDECIDE to make insulin recommendations a current glucose reading 
is necessary.  With the introduction of HealthKit, several diabetes technology device 
manufacturers have released companion apps that allow glucose meters and CGMS to 
automatically share their data with HealthKit.  The HealthKit framework stores all 
health-related data locally on the phone and allows all data, with permission from the 
user, to share data points with other apps installed on the phone.  iDECIDE takes 
advantage of the HealthKit framework and when granted permission by the user, 
iDECIDE can read and write glucose data points to and from the framework on the 
phone.  Not only are the glucose readings integrated to HealthKit, but nutrition content 
and body weight are other data points that iDECIDE contributes to the HealthKit data 
ecosystem. 
8.6 Conclusion 
The iDECIDE evidence-based algorithm for making insulin and carbohydrate 
recommendations has been deployed as an app for the iOS platform.  As a smartphone 
app, iDECIDE can easily be disseminated at a low cost to patients. The iDECIDE app as 
it is currently implemented is ready for prospective testing.  There also lies the potential 
for patient-generated data from the iDECIDE app to be connected to the Epic EHR, 
which can grant physicians more timely access to patient data.  
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9 CONCLUSION 
Type 1 diabetes is a complicated disease that requires patients to interact with 
various technologies in order to self-manage blood glucose and avoid complications that 
arise from glycemic excursions [2].  Patients are more likely to adhere to treatments when 
they incorporate personal lifestyle choices [20,26].  Two lifestyle choices that influence 
glucose control are exercise and alcohol consumption [11,13,15,17,43,45].  Current 
diabetes technologies do not account for exercise and alcohol when making insulin bolus 
suggestions [29].  The hypothesis is postprandial blood glucose levels of adult patients 
with T1D can be improved by providing insulin bolus or carbohydrate recommendations 
that account for meal and alcohol carbohydrates, glycemic excursion, and planned 
exercise. 
The solution proposed is iDECIDE, an evidence-based decision support tool that 
suggests insulin or carbohydrates to improve glucose control and it is deployed as a 
smartphone application.  This research demonstrates that the iDECIDE decision aid is not 
inferior to the Medtronic MiniMed, Inc. [28] IPBC, providing equivalent 
recommendation in 63% and outperformance in 23% of cases.  iDECIDE’s alcohol 
recommendations may have provided an advantage in 64% of cases, while 
recommendations for exercise with a duration less than 90 minutes could have improved 
post-exercise BG in 81% of cases.  
One of the limitations to this research stems from the demographics of the 
participants.  All participants were recruited from the endocrinology department at the 
Arizona Mayo Clinic.  The population was well controlled with a mean HbA1c score of 
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7.5%.  A smaller, but overlapping population, was given portions of the short test of 
functional health literacy in adults (S-TOFHLA) and all participants received a perfect 
score.  Also, almost all patients approached for participation owned smartphones, and of 
those that did participate nearly all owned an Apple smartphone.  Due to the homogeneity 
of the atypical population, the results may not be generalizable.  The iDECIDE decision 
aid was extended to include exercise and alcohol in order to incorporate lifestyle 
preferences, and other factors that influence glucose levels were not included, such as 
stress, medications and hormones. 
The results of iDECIDE’s performance in the case of alcohol consumption were 
not conclusive, which was in part due to a small sample size.  Others have assessed 
alcohol behaviors in emerging adults with T1D via questionnaires and surveys [154,155], 
but to our knowledge, ours was the first attempt to gather and analyze alcohol behaviors 
from free-living patients self-tracking with a smartphone app.  
This research has implications for various stakeholders.  For example, the 
literature review and the study of self-management behaviors (Aims 1 & 2) can inform 
diabetes technology researchers as they develop and design future diabetes technology 
and devices.  The results from the study of self-management behaviors (Aim 2), indicate 
that self-reported behaviors do not always translate into actual behaviors recorded by 
self-tracking and/or diabetes technology.  The analytical techniques we used to assess 
patients’ behaviors and compensation techniques can guide the development of bed-side 
tools for clinicians that could support shared-decision making and treatments.  Also 
ongoing is the analysis of the qualitative data regarding self-reported compensation 
  
124 
 
techniques for exercise and alcohol  as well as the perceptions on the effects of exercise 
and alcohol on BG control [156].  
The novel methods developed to compare and assess iDECIDE’s 
recommendations (Aim 4) can be applied more broadly in order to identify, calibrate and 
assess other bolus calculators before undergoing costly clinical trials.  It also opens the 
possibility of using non-traditional sources of data for conducting research.  The 
OpenAPS (Open Artificial Pancreas System) data repository [157], under the umbrella of 
the Open Humans project [158], has provided a means where individuals with T1D can 
upload and donate their data.  Traditional researchers can propose research studies and 
the OpenAPS community determines which projects will be granted access to the donated 
data.  Future work with real-life data from a broader population, like that of OpenAPS, 
could improve the generalizability of the results from assessing bolus calculators with the 
proposed methods. 
When the iDECIDE decision aid is deployed as a smartphone app for the Apple 
iOS platform (Aim 5) it benefits patients and clinicians.  There is the potential for 
clinicians to have more timely access to patient data, such as and receiving alerts when 
pre-determined thresholds for blood glucose are crossed.  This functionality for clinicians 
requires the integration of Apple’s HealthKit with Epic’s patient portal, MyChart, which 
has been accomplished by other healthcare institutions that already use the Epic EHR 
[152,153].  Patients can conveniently download the app to their smartphone and receive 
decision support that integrates with other HealthKit enabled apps and devices.  Currently 
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the iDECIDE app is going through the necessary requirements to receive FDA approval 
and there are plans to pursue a prospective randomized clinical trial. 
This research is an example of using novel informatics data collected by existing 
diabetes technologies and self-reported by patients to understand the burden of the 
disease and influence the design of a solution.  Multiple sources of heterogenous and 
disparate data were gathered, collated and analyzed.  Data sources included a self-report 
via interview and/or survey, real-time self-record via paper logs/smartphone app, and 
data generated by medical devices, e.g. insulin pump and glucose monitors/meters.  There 
were no existing methods to retrospectively assess iDECIDE’s recommendations and 
hence part of this research incorporated the development of a novel methodology that 
uses patient-generated data to retrospectively compare bolus calculators.   
The proposed novel decision aid and comparison methodology present practical 
solutions that can be applied to broader range of problems, such as T2D and other chronic 
diseases, and to other lines of research, such as collaboration with patient-controlled 
diabetes data repositories, including additional factors that affect glucose levels, and 
further identifying patient profiles to inform the development of personalized therapies to 
improve adherence.  The identification of correlating behaviors with respect to insulin 
pump usage and compensation for exercise and alcohol could lead to the creation of 
patient profiles that would allow clinicians to personalize treatments regimens that target 
increased adherence and result in improved glycemic control.  Furthermore, iDECIDE 
could be extended to include other factors that affect glucose control (e.g. stress, 
hormones, and medications), and user-reported or device-recorded data could be used to 
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retrospectively calibrate and assess the performance of the new parameters included in 
the decision aid using the methods described in Chapters 6 & 7.  
There are many other chronic diseases (e.g. congestive heart failure, asthma, 
hypertension), whose treatment therapies require patients to engage in self-care at home, 
that could benefit from the methodologies presented in this dissertation.  Reviews of 
mobile technology based interventions for chronic diseases management report positive 
effects, including improved provider and patient adherence to practice guidelines as well 
as health outcomes [122,159].  Many of the studies included in these reviews did not 
collate data from heterogenous sources and few had a decision support system in place.  
Most of the studies relied heavily on providers to access, gather, and analyze the data in 
order to personalize treatment therapies on the fly and initiate phone calls or text 
messaging to relay treatment changes.  These resource intensive mobile-based 
interventions could benefit from several aspects of the work presented related to 
iDECIDE.  The methods used to understand and define user needs (Chapters 2,3 and 4) 
could be used to develop a decision aid aimed at assisting providers by extending the 
framework depicted in Figure 8.2 to account for scenarios where providers adjust aspects 
of the treatment plan, e.g. changing ICR or CF settings.  The provider-specific decision 
aid could be assessed by adapting the performance assessment methods presented in 
Chapters 6 and 7 using real-life patient and provider generated data.   
Future work with iDECIDE could migrate to patients with T1D who do not use 
insulin pumps or to type 2 diabetes (T2D).  Similar to T1D, suboptimal adherence to self-
management guidelines for T2D results in poor glycemic, blood pressure and lipid 
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control, which can lead to increased morbidity and mortality rates [160].  All patients 
with T1D require insulin therapy and it is necessary for about half of patients with T2D to 
achieve glycemic control [161].  Glucose control within the United States is poor with 
about 50% of patients with T2D that achieve target HbA1c scores [162].  Currently much 
of the data generated by patients with T2D is recorded with paper logs.  The efficacy of 
changes to treatments are more difficult to assess with fewer objectively gathered data 
points, and iDECIDE could prove useful in providing a better snapshot of of patients’ 
self-care at home.  Clinicians and patients would then be able to make better informed 
decisions regarding adjustments to treatments and therapies to improve adherence and 
outcomes. 
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